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A ROLE FOR RAGE SYSTEM ACTIVATION IN PRETERM BIRTH. Margaret A. 
Baumbusch, Catalin S. Buhimschi, Guomao Zhao, Emily A. Oliver, Irina A. Buhimschi. 
Department of Obstetrics, Gynecology and Reproductive Endocrinology, Yale 
University, School of Medicine, New Haven, CT. 
The receptor for advanced glycation end products (RAGE) is a multiligand pattern 
recognition receptor involved in transducing endogenous damage associated stimuli into 
inflammatory responses. Advanced glycation end products (AGEs), HMGB1 
(amphoterin) and S100 proteins, such as S100B, are prototype RAGE ligands, while 
soluble RAGE (sRAGE), a product of RAGE activation, acts as a ligand scavenger and 
RAGE inhibitor. We propose that RAGE may play important yet distinct pathogenic 
roles in both inflammation-induced preterm birth and preeclampsia and that, while 
inflammation-induced preterm birth associates with fetal RAGE activation, preeclampsia 
induces a maternal state of RAGE activation. We sought to identify the putative stimuli 
and implications for the opposing types of RAGE activation in these two leading causes 
of prematurity. Biological samples from two cohorts of prospectively enrolled women 
were analyzed. In women with symptoms of preterm birth who were assessed to rule out 
intra-amniotic infection, we measured amniotic fluid for HMGB1 and cord blood for 
HMGB1 and S100B. For ex vivo validation of our findings, HMGB1 was also measured 
in tissue explants subjected to endotoxin. From women assessed clinically to rule out 
preeclampsia, blood and urine of three subgroups (severe preeclampsia, healthy controls, 
and chronic hypertension but no preeclampsia) were used to determine levels of AGE and 
HMGB1 as potential stimuli for RAGE activation. Immunohistochemisty on reproductive 
tissues was used on select cases in both cohorts for cellular localization and validation of 
 
immunoassay findings. We found that HMGB1 levels are increased in amniotic fluid of 
women with intra-amniotic inflammation and preterm birth, and the likely source is the 
damaged amniochorion, as demonstrated by explant experiments and immuno-
histochemistry. Cord blood levels of HMGB1 correlate with the extent of fetal 
inflammation and S100B but not with either the level of intra-amniotic infection or 
amniotic fluid HMGB1, indicating that other RAGE axis modulating molecules may play 
a role. We confirmed that severe preeclampsia is associated with elevated sRAGE, a 
product of RAGE activation, but that neither serum AGE nor HMGB1 levels mirrored the 
changes in sRAGE. In contrast, women with severe preeclampsia and especially those 
with HELLP and/or eclampsia had significantly elevated HMGB1 excretions that 
correlated directly with circulating sRAGE.  
In conclusion, this research further provides evidence for a biologically relevant 
role of HMGB1 in driving the distinct types of RAGE activation in two major obstetrical 
complications leading to prematurity. Heightened fetal HMGB1-RAGE axis activation 
may play a role in intra-amniotic inflammation while a maternal HMGB1-RAGE system 
may contribute to pathogenesis of preeclampsia. 
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1. PRETERM BIRTH 
1. 1. Classification and general considerations 
Preterm birth, defined as birth before 37 completed weeks of gestation, is a significant 
public health problem and the leading cause of perinatal mortality worldwide [1,2]. 
Preterm birth is generally classified as either spontaneous, following preterm labor with 
intact membranes or preterm premature rupture of membranes (PPROM), or medically 
indicated, when physicians artificially interrupt the course of pregnancy for maternal or 
fetal indications. Medically indicated preterm birth accounts for approximately 30 to 35 
percent of preterm births, while 40 to 45 percent follow preterm labor, and 25 to 30 
percent follow PPROM [3]. 
 In 2006 the prevalence of preterm birth rose to an unprecedented 12.8 percent in 
the United States, a 21 percent increase since 1990, despite advances in medical care 
[4,5]. Other developed countries report rates of preterm birth between five and nine 
percent [3]. Five percent of preterm births occur at less than 28 weeks (extreme 
prematurity), approximately 15 percent at 28 to 31 completed weeks (severe 
prematurity), about 20 percent at 32 to 33 completed weeks (moderate prematurity) and 
60 to 70 percent at 34 to 36 completed weeks (near-term) gestation [3]. In the United 
States, over 500,000 premature infants are born annually [4], 60,000 of which have a 
birth weight less than 1,500 grams [6]. While early preterm birth (less than 34 weeks 
gestation) has increased 10 percent since 1990, late preterm birth (34 to 36 completed 
weeks gestation) has increased 25 percent [4,5]. Much of this increase in preterm birth 
has been attributed to medically indicated preterm birth [7]. Multiple births, which tend 
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to deliver earlier than singletons, have contributed to the rise in preterm birth, however 
substantial increases in preterm birth rates are also seen in singleton births [4]. Assisted 
reproductive techniques have also contributed to the overall increase in preterm births in 
two ways: increased multiple gestations and increased preterm birth in singleton 
pregnancies after in vitro fertilization [3].  
 Preterm birth is impacted by significant racial disparity, and understanding the 
underlying causes of this disparity has been a major public health concern. As of 2003, 
preterm birth occurs in 11.7 percent of non-Hispanic white births, 18.4 percent of non-
Hispanic black births and 12.2 percent of Hispanic births [5]. The preterm birth rate for 
non-Hispanic blacks declined during the 1990s but has risen six percent since 2000, and 
the substantial racial gap in infant mortality has been linked to the higher rate of infants 
born at very short gestation in minorities [5]. Black women are three to four times more 
likely to have a very early preterm birth than women from other racial and ethnic groups, 
even when controlling for socioeconomic and maternal behavior characteristics [3].  
 A previous preterm delivery is a major risk factor for preterm birth in a 
subsequent pregnancy, and for unknown reasons this relationship holds true for both 
spontaneous and medically indicated preterm birth [8]. Interestingly, women who have a 
medically indicated preterm birth in their first pregnancy are at greater risk to deliver 
preterm subsequently, for either medical indications or spontaneously [7,8].  
 Clinically predicting preterm birth is for obvious reasons a topic of great interest. 
While a history of preterm birth is a reasonable indicator of increased risk of subsequent 
preterm birth, this information is not available to women during their first pregnancy. 
This challenge has spurred research into factors that may be able to predict with 
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reasonable accuracy preterm birth in nulliparous women, who comprise about 40 percent 
of pregnancies in the United States [4]. A retrospective study in a large cohort of 
nulliparous women confirmed that the risk of preterm birth in this population is about 12 
percent. The same study also found that none of the current models using maternal 
characteristics or screening tests already implemented in practice is sufficiently 
informative to allow case selection to mitigate interventions in nulliparous women [9]. 
1. 2. Sequelae of prematurity 
The first premature nurseries existed and the first books on the care of the newborn were 
written as early as the 1930s and 1940s in the United States. But it was not until the late 
1960s and early 1970s that major changes in clinical care occurred, including 
miniaturization of blood samples needed for analysis and the ability to provide 
intravenous nutritional support and maintain normal body temperature. By 1975, 
neonatology-perinatology had become a subspecialty board of the American Board of 
Pediatrics. Prior to the widespread use of assisted ventilation in the 1970s, few neonates 
survived birth before 28 gestational weeks. The increasing and earlier use of antenatal 
corticosteroids, postnatal surfactant administration and assisted ventilation, as well as the 
evolution of neonatal intensive care, dramatically improved the survival rates by the mid-
1990s for very preterm births, especially those before 28 weeks. In 1960 a 1,000 gram 
infant (approximately 28 weeks) had a mortality rate of 95 percent [10]. By 2000 that 
statistic had flipped to a 95 percent chance of survival [11]. Infants born at less than 28 
weeks gestation in 1960 were considered previable [10]. Today over 50 percent of infants 
born at 24 weeks gestation survive, and the limit of viability is considered 23 to 24 weeks 
[12].  
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 Improvements in neonatal intensive care have led to increased survival of preterm 
infants but also increased disability and a heightened awareness of the need to improve 
neonatal outcomes associated with prematurity [13]. Today preterm birth accounts for 75 
percent of perinatal mortality and more than half of long-term perinatal morbidity [3]. 
Gestational age has the greatest impact on outcomes of preterm birth, followed by birth 
weight. Infants born at less than 32 weeks of gestation comprise approximately one-third 
of deaths in the perinatal period [14], and 67 percent of deaths occur in infants less than 
2,500 grams (about 36 weeks) [11]. Thus, while prematurity is a harbinger of poor 
outcomes, it is the smallest and youngest neonates who are at the greatest risk and thus 
pose the greatest challenge to the clinical decision-maker.  
 Conventional wisdom holds that the primary causes of the high neonatal 
morbidity and mortality attendant preterm birth are complications of immature organ 
systems, such as respiratory distress syndrome, intraventricular hemorrhage, necrotizing 
enterocolitis, bronchopulmonary dysplasia and white matter disorders. In 2005 the cost of 
caring for premature infants in the United States was estimated at $26.2 billion per year, a 
figure that excludes long-term care costs [15]. The societal burden of prematurity is 
further underscored by the fact that medical and other supportive care expenses exceed 
the estimated lifetime earnings per survivor with a birth weight of less than 900 grams 
(approximately 27 weeks of gestation) [16]. 
 Fifty percent of premature infants have long-term neurological handicaps, 
including blindness, deafness, developmental delay and cerebral palsy [17,18,19]. The 
prevalence of cerebral palsy is inversely related to gestational age. Approximately five 
percent of the nearly 55,000 preemies who survive the newborn period exhibit cerebral 
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palsy, and 25 to 50 percent have cognitive and behavioral deficits [6]. The consequences 
of prematurity, however, are not restricted to severe neurological handicaps. Even 
premature infants with relatively uncomplicated neonatal courses are at risk for 
developmental delays in motor skills, lower cognitive performance and learning 
difficulties, as well as behavioral, psychological and social impairments [20,21]. Very 
preterm infants born at less than 32 completed weeks gestation without major 
neurological deficits have a two- to three-fold increase in behavioral problems, such as 
hyperactivity, conduct problems and emotional symptoms [22]. Premature infants also 
attain slightly but significantly lower rates of educational achievement, employment and 
independent living [21].   
 Prematurity is a major cause of infant death, and survivors are at significant risk 
of serious long-term disability. Preterm birth rates continue to rise despite advances in 
prevention and treatment, and preterm birth remains one of the most complicated 
research and public health issues in the fields of obstetrics and pediatrics. Understanding 
the etiologies of preterm birth and identifying specific biomarkers to identify at-risk 
patients are keys to developing targeted interventions to prevent prematurity and its 
attendant problems.  
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2. SPONTANEOUS PRETERM BIRTH 
2. 1. Spontaneous preterm birth, a heterogeneous syndrome  
From a clinical standpoint spontaneous preterm birth debuts as either increased uterine 
activity accompanied by cervical ripening or PPROM. The current view is that regardless 
of its clinical manifestation spontaneous preterm birth results from the clinical 
convergence of multiple yet distinct pathophysiological pathways, including intrauterine 
inflammation, uterine over-distention, utero-placental circulatory disturbances (ischemia 
or hemorrhage) and stress, including oxidative (redox) imbalance [23]. An increased 
level of activation of the maternal or fetal hypothalamic pituitary axis has been quoted as 
responsible for a subgroup of preterm births characterized by increased concentration of 
corticotropin releasing hormone (CRH) and decreased CRH binding protein in maternal 
circulation [24]. Furthermore, systematic placental histological studies identified fetal 
eosinophilic gradients in nearly one-fifth of the cases of spontaneous preterm birth, 
pointing to fetal allergy as an associated component, especially in instances where acute 
inflammation was also found [25]. 
Because of the multitude of 
pathways leading to preterm birth 
and different levels of intricacy 
among effectors, the initial triggers 
remain for the most part unknown. 
A schematic representation of the 
current understanding of the 
 
Figure 1: Proposed view of how multiple etiologies 
and pathogenic pathways converge into the clinical 
manifestations of spontaneous preterm birth. 
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etiologic, pathogenic and clinical circumstances associated with spontaneous preterm 
birth is shown in Figure 1.  
2. 2. Relevance of infection as a pathogenic pathway to preterm birth 
The heterogeneous nature of preterm birth is substantiated by the findings that not all 
preterm births are equal with respect to their contribution to prematurity sequelae. 
Evidence suggests that the poor outcomes of many children delivered prematurely are not 
entirely dependent on their gestational age at birth and birthweight [26,27]. When 
adjusted for gestational age at birth, it appears that intrauterine infection and subsequent 
inflammation contributes disproportionately to neonatal mortality and morbidity 
compared to other etiologies, suggesting that the associated intrauterine processes may 
adversely affect the fetus in utero prior to birth [28]. The implication of this finding is 
important: the intrauterine environment may be harming instead of protecting the fetus. 
Therapeutic interventions solely aimed to extend gestation or unilaterally to treat 
infection without addressing the consequent host response, therefore, may have more 
deleterious consequences than prematurity alone [29]. This conundrum has been 
substantiated by the 2008 childhood outcome results of the ORACLE I and II clinical 
trials that show antibiotics given to women in threatened preterm labor or with PPROM 
increase rather than decrease the risk of cerebral palsy [30,31]. These results suggest that 
while antibiotics induce suppression of bacteria they fail to quell the inflammatory 
processes already underway and the causes of fetal cellular damage.   
 Evidence from humans [32] and animal models [33] suggests that intrauterine 
inflammation in response to infection may evolve silently. The fetus is therefore 
adversely affected by host defense mechanisms before the onset of signs and symptoms 
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of preterm birth [34]. In such cases, prematurity may be inappropriately cited as the only 
cause of perinatal mortality or morbidity [35].  
 The prevalence of infection as a cause of preterm birth is higher the younger the 
gestational age at the onset of clinical manifestations [36]. Simply put, infections are 
responsible for most severe forms of prematurity. One study showed that 67 percent of 
patients delivering at 21 to 24 weeks gestation had chorioamnionitis, as compared to 23 
percent at 33 to 36 weeks gestation. Further, the severity of chorioamnionitis was greater 
with preterm compared to term delivery [37]. Evidence of intra-amniotic infection 
appears to be more common in preterm births presenting with PPROM than in cases 
presenting with uterine contractions and intact membranes, suggesting that cellular 
destruction within vital fetal tissues and organs may silently mirror the processes leading 
to dissolution of the amnion and chorion in PPROM [38,39]. Overwhelming evidence 
supports the conclusion that intra-amniotic inflammation superimposed on prematurity 
can lead to more devastating consequences for the neonate than prematurity alone 
[33,40,41,42,43]. 
 That approximately only 25 to 40 percent of preterm births are the result of 
infection is likely underestimated given the difficulty in detecting intrauterine infection 
with conventional culture techniques [3,44]. Using DNA-based techniques, a recent study 
showed that the process of intra-amniotic infection involves uncultivated or difficult-to-
cultivate bacterial species that induce a potent host response [44]. 
In addition to its impact prior to birth, intrauterine infection is a risk factor for 
early-onset neonatal sepsis (EONS) [45], which occurs in approximately 15 to 19 per 
1,000 live births in infants weighing less than 1,500 grams [46]. Prematurity itself 
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directly predisposes to commensal infections due to prolonged intravascular access and 
mechanical ventilation, explaining why both early- and late-onset sepsis occur with 
increased frequency in premature neonates [13,47,48,49]. For the same reasons, in 
statistics published by Yale-New Haven Hospital, which holds the longest running, 
single-center database of neonatal sepsis started in 1928, mortality attributable to sepsis 
remains at 11 percent despite advances in neonatal care [45].  
2. 3. Intrauterine infection, inflammation and fetal damage 
As detailed above, preterm infants are at substantial risk of developing neonatal 
infections that, combined with their immaturity, lead to poor outcomes. The exact 
mechanisms translating intrauterine infection into cellular damage, however, are not well 
understood and seem to involve particularities of the fetal and neonatal response to 
infection that cause pathology unique to the premature fetus, including heightened 
inflammatory and oxidative states that act synergistically with microbial insult.  
 Host defense mechanisms can be grouped into innate and adaptive processes. 
Innate immunity includes the inflammatory reactions of neutrophils and monocytes, 
while adaptive immunity refers to lymphocytes responses that recognize specific 
microbial antigens. Both innate and adaptive immunity have evolved phylogenetically to 
counteract and clear pathogens to prevent tissue injury [50] and rely on the host’s ability 
to sense when potentially dangerous microorganisms intrude. Several classes of microbial 
sensing proteins have been described, the most intensely studied of which are Toll-like 
receptors (TLRs) that detect microbes in the extracellular compartments [51]. More 
recently other classes of sensing proteins have been discovered. These include NOD-like 
receptors (NLRs), with roles in intracellular cytosolic surveillance, and the membrane-
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associated C-type lectins (CLRs), which bind glycosylated ligands [52,53]. Irrespective 
of class or location, however, these protein sensors mitigate host defense through 
engagement of ubiquitous and conserved bacterial constituents known as pathogen-
associated molecular patterns (PAMPs) [54]. Upon engagement of PAMP epitopes, 
sensing receptors elicit the release of inflammatory chemokines and cytokines primarily 
through TLRs, including interleukin (IL)-8, IL-1β and tumor necrosis factor (TNF) α, 
which in turn stimulate release of other inflammatory mediators and recruit inflammatory 
cells, such as neutrophils, monocytes and macrophages, to the respective sites of injury 
[51]. These inflammatory cells produce a variety of bacteriostatic and bactericidal 
molecules along with free radicals, reactive oxygen species and matrix degrading 
enzymes (matrix metalloproteases) aimed primarily to neutralize bacteria. 
 For obvious reasons mounting an adequate inflammatory response is critical for 
intact survival of the mother and fetus. To be successful this effort has to assure the 
correct discrimination between self (host) and microorganisms, and the inflammatory 
reaction must cease once the intruding germs have been annihilated. Evidence suggests 
that in pregnancies complicated by infection-induced preterm birth the checks and 
balances of the innate immune response may be imperfect and result in an inappropriate 
trigger and control of the inflammatory course [55,56,57].  
 Even after adjustment for gestational age at delivery, strong correlations exist 
between the level of intrauterine and/or fetal inflammation (as reflected by elevated 
cytokine levels in the fetal circulation) and histological chorioamnionitis and the 
incidence of perinatal complications [57,58,59]. Numerous inflammatory cells are found 
in the lungs of neonates born to women with chorioamnionitis, and the resulting 
 11 
pneumonitis is considered an important contributor to bronchopulmonary dysplasia in 
these infants [60,61,62]. Other studies have established synergistic relationships between 
intrauterine inflammation and important adverse neonatal outcomes, including 
intraventricular hemorrhage, necrotizing enterocolitis, retinopathy of prematurity and 
long-term handicaps, such as cerebral palsy [13,59,63,64].  
Fetal systemic and central nervous system inflammation are critical to the genesis 
of brain injury in the neonate [65]. A growing body of evidence supports the notion that 
umbilical cord vasculitis (funisitis), elevated neurotoxic cytokines and sepsis in children 
with cerebral palsy are preceded by a robust intra-amniotic inflammatory response 
[13,57,62,66,67]. Bacterial endotoxins are known to cause white matter injury in preterm 
animal models [68]. In humans, extremely low birth weight infants (401 to 1,000 grams 
at birth) with sepsis have 50 to 100 percent higher rates of cognitive deficits, cerebral 
palsy and other neurodevelopmental disabilities compared to non-infected infants [69]. 
Links among sepsis, brain injury and adverse outcomes in preterm infants have long been 
proposed [70,71]. The mechanisms mediating periventricular leukomalacia, the most 
common ischemic brain injury in preterm infants, in premature neonates with sepsis are 
postulated to include injury to pre-oligodendrocytes induced by free radicals, reactive 
oxygen species and inflammatory cytokines [70]. Injuries to endothelial cells induced by 
similar mechanisms add to the damage, leading to multisystemic organ dysfunction [72]. 
Taken together, these observations suggest that, whereas an adequate innate and adaptive 
immune response is critical for the survival of mother and child, excessive inflammation 
is associated with adverse outcomes in newborns [73]. 
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Recent evidence from adults indicates that not only pathogen PAMPs can trigger 
an inflammatory reaction but also endogenous molecules described collectively as 
damage-associated molecular pattern molecules (DAMPs) [74], including high mobility 
group box protein-1 (HMGB1), S100 proteins, heat-shock proteins, uric acid and DNA. 
DAMPs are abundant intracellular proteins that when released in excess in the 
extracellular compartment as a result of cell death or injury become “danger signals” that 
activate immune cells and induce further damage to host cells [75]. Owing to their 
similarity to cytokines and their release by activated or damaged cells under conditions of 
cell stress, these endogenous pro-inflammatory molecules have also been termed 
alarmins [76]. A common feature of DAMPs is the ability to engage the receptor for 
advanced glycation end products (RAGE), which results in uncontrolled activation of 
inflammation. An important feature of the RAGE receptor is that its expression is low in 
normal tissues but increases transcriptionally in environments where RAGE ligands, such 
as DAMPS, accumulate, escalating tissue damage through positive feedback [77]. As will 
be described in the following sections, fetal RAGE activation may represent the elusive 
stimulus for the transition from the adequate inflammation aimed to protect the fetus to 
the maladaptive phenomenon characterized by cellular destruction.  
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3. PREECLAMPSIA AND INDICATED PRETERM BIRTH 
3. 1. Preeclampsia, an elusive pregnancy-specific disorder 
Preeclampsia is a pregnancy-specific hypertensive disorder of unknown etiology and a 
major cause of maternal and fetal morbidity and mortality. Preeclampsia complicates 
approximately six to eight percent of pregnancies and accounts for 15 percent of all 
preterm births [78,79]. This disease is responsible for 20 percent of pregnancy-related 
maternal deaths in the United States [80] and more than 76,000 deaths worldwide each 
year [81]. Importantly, preeclampsia is the leading cause of medically indicated preterm 
birth [7,8,82].  
Preeclampsia is characterized by heterogeneous clinical and laboratory findings 
and can be classified as a maternal disorder, fetal disorder (growth restriction) or both. 
While currently defined as the onset of hypertension (≥140/≥90 mmHg) and proteinuria 
(≥0.3g in 24 hours) after 20 weeks gestation in a previously normotensive woman, 
preeclampsia is primarily a clinical diagnosis and should also be considered when 
hypertension and proteinuria are associated with persistent cerebral symptoms, epigastric 
or right upper-quadrant pain with nausea or vomiting, or thrombocytopenia and abnormal 
liver enzymes [83]. Severe preeclampsia is diagnosed in the presence of severe 
hypertension (≥160/≥110 mmHg), proteinuria or multiorgan involvement, such as 
pulmonary edema, seizures (eclampsia), oliguria, thrombocytopenia, abnormal liver 
enzymes associated with persistent epigastric or right upper-quadrant pain, or persistent 
and severe neurological symptoms, such as altered mental status, headaches, blurred 
vision or blindness [83]. In addition, preeclampsia is also considered severe if 
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accompanied by symptoms of end-organ damage, such as HELLP syndrome (defined as 
hemolysis, elevated liver enzymes or low platelet counts) or fetal growth restriction. 
Prior to the 19th century, the term eclampsia referred to the observation of 
convulsions occurring in a pregnant woman that ceased after delivery [84]. In 1840, the 
French pathologist Pierre Rayer demonstrated proteinuria in three edematous pregnant 
women. In 1843 John Charles Lever of London, struck by the resemblance of eclamptic 
patients to those with nephritis, published the observation that nine out of 10 convulsing 
women had albuminuria as a “precursor of puerperal fits” [85]. In the same month 
(November 1843), Sir James Young Simpson recognized that “patients attacked with 
puerperal convulsions had almost invariably aluminous urine […] in some rather 
preceding dropsical complication” [85]. In observing albuminuria, Lever and Simpson 
are thus credited with the first recognition of a subclinical abnormal state preceding 
eclampsia. Albuminuria thus represented the first tool that could be used to predict 
toxemia and prevent convulsions. The realization that hypertension was also present in 
these cases did not occur until the invention of the sphygmomanometer with inflatable 
armband by the Italian physician Scipione Riva-Rocci in 1896 and its subsequent 
application to obstetrics after 1910.  Our obstetrics predecessors found an incidence of 
eclampsia of approximately one in 500 pregnancies, with a maternal mortality of 20 to 30 





3. 2. Challenges in diagnosis and management of preeclampsia 
Preeclampsia, as it is defined today, is diagnosed only after the assessment of urinary 
proteins and blood pressure, proteinuria and hypertension thus replacing the prior 
diagnostic gold standard of “convulsions in a pregnant woman.” To this day the goal is to 
be able to predict who is going to develop preeclampsia as early as possible, and research 
efforts have intensified to find the best combination of altered markers before a women 
becomes hypertensive or proteinuric. Even today, despite advances in diagnosis, the only 
definitive cure for preeclampsia remains delivery. Identifying new markers may aid 
clinicians with case management when contemplating early interruption of the pregnancy 
course when clinical signs and symptoms are less clear-cut. On the other hand, if the 
markers are pathogenically related to the cause of preeclampsia, perhaps they will point 
us to new ways to treat preeclampsia and avoid its progression to the clinically manifest 
syndrome. Figure 2 is a representation of how the delineation of the preeclampsia 
syndrome has and perhaps will continue to evolve historically along with our progress in 
elucidating the factors responsible for this condition. As this progress is markedly 
influenced by technological advances in diagnostic tools, it is expected that future 
developments in fields like genomics and proteomics may allow identification of 
Figure 2: Proposed 
view of how our ability 
to detect an abnormal 
subclinical state 
preceding manifest 
disease has and likely 











biomarkers reflective of an abnormal state that precedes the onset of clinical 
manifestations as defined today (proteinuria and hypertension) or the gestational cut-off 
of 20 weeks. Such a state will then require new terminology, perhaps “pre-preeclampsia.”  
The current difficulty in diagnosing preeclampsia lies in part in the fact that many 
women present with a constellation of signs and symptoms inconsistent with the current 
diagnostic criteria. In fact, some women who develop severe gestational hypertension 
without proteinuria have higher maternal and perinatal morbidities than those with mild 
preeclampsia [86,87]. Furthermore, hypertension and/or proteinuria are absent in 10 to 20 
percent of women who develop HELLP syndrome [88] and in 38 percent of women who 
develop eclampsia [89], two complications of preeclampsia that are associated with 
significantly higher rates of maternal and perinatal morbidities than mild preeclampsia.  
About one to five percent of pregnant women have chronic hypertension, defined 
as sustained hypertension present before conception or prior to 20 weeks gestation [90], 
and rates are increased with obesity, diabetes and advancing maternal age, as well as in 
African Americans. The current criteria for preeclampsia diagnosis are unreliable in 
women with pre-gestational hypertension or proteinuria or in those women presenting for 
their first prenatal care assessment after 20 weeks gestation [83]. In such cases markers 
other than proteinuria and hypertension are needed to guide practitioners in their 
diagnosis and with regard to the appropriate timing of intervention. Although at this time 
there is no etiologically or pathogenically targeted therapeutic arsenal for preeclampsia, 
practitioners would like to postpone delivery as long as safely possible while balancing 
the degree in clinical worsening of the maternal condition with the degree of prematurity 
or fetal distress. In addition, antenatal steroid administration has clearly been shown to 
 17 
reduce the risk of respiratory distress, the need for respiratory assistance and overall 
neonatal mortality [91]. This, however, requires obstetricians to precisely initiate 
corticosteroid prophylaxis at least 48 hours but not more than one week prior to birth, a 
difficult task in the current clinical practice. Given the devastating consequences of 
preeclampsia, any sign of maternal decompensation rapidly prompts toward delivery 
even in the absence of a complete steroid course. 
The only definitive treatment for preeclampsia is delivery of the fetus and of the 
placenta, a decision that is particularly concerning for both medical practitioners and 
pregnant women at young gestational ages. The task becomes even more challenging 
when a pre-existing hypertensive or renal disorder makes differentiating preeclampsia 
from similar clinical syndromes difficult, thus clouding the clinical picture and further 
complicating the decision to deliver preterm. For example, while chronic hypertension 
predisposes to preeclampsia and placental abruption, thus increasing neonatal morbidity 
and mortality, chronic hypertension uncomplicated by preeclampsia is usually a benign 
pregnancy complication.  
In the United States, where preterm infants are cared for in advanced neonatal 
intensive care units, obstetricians are less concerned with mandated delivery beyond 34 
weeks of gestation. Mandated delivery before 34 weeks gestation, however, is 
unanimously considered a poor pregnancy outcome. Given the finality of treatment by 
delivery, it is vitally important for research to uncover methods to definitively diagnose 
preeclampsia and thus correctly identify those cases that mandate delivery.  
 Because of the high rates of maternal and fetal morbidity and mortality associated 
with preeclampsia and high neonatal survival beyond 34 weeks of gestation, it is 
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generally agreed that patients should be delivered if disease develops at greater than 34 
weeks of gestation [92,93]. This shift in management has led to a sharp rise in the 
incidence of late preterm births (33 to 36 weeks of gestation). Although the true 
consequences of this interventional management for neonatal and childhood outcomes 
has yet to be determined, some recent studies have suggested an increased risk of 
mortality and morbidity in late preterm newborns compared with infants born at term. In 
a large population cohort perinatal, neonatal and infant mortality rates were significantly 
higher in the late preterm group. Infants in this group needed resuscitation more often, 
had a significantly higher incidence of respiratory morbidity and infections and had a 
significantly longer duration of hospital stay than newborns in the term group [94]. 
Furthermore, children born late preterm are over three times more likely to be diagnosed 
with cerebral palsy than children born at term [95]. In this context obstetricians need to 
weigh very carefully the risks versus benefits when opting for an indicated preterm 
delivery even at near-term. The real challenge, however, remains in determining the best 
clinical course in pregnancies less than 34 weeks of gestation, when severe preeclampsia 
alone is associated with high rates of perinatal morbidity and mortality [96]. 
Temporization of delivery may lead to in utero fetal death or asphyxial damage, as well 
as an increase in maternal morbidity, while immediate delivery will unambiguously lead 
to high neonatal morbidity and mortality due to prematurity, as well as prolonged 
hospitalization in the neonatal intensive care unit. Two randomized clinical trials 
conducted since 1990 have attempted to address this issue, both of which support 
expectant management (glucocorticoid therapy for lung maturation followed by delivery 
only for specific maternal or fetal indications) in a select group of patients (stable 
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maternal and fetal conditions) with severe preeclampsia at 28 to 34 weeks of gestation 
[92,93]. The goal of such management is to improve perinatal outcome by prolonging 
gestation and reducing neonatal morbidities without increasing maternal morbidity. 
Several recent retrospective and observational studies have extended the recommendation 
for expectant management for severe preeclampsia at 24 to 34 weeks of gestation [96]. 
For gestational ages less than 23 completed weeks of gestation, expectant management is 
associated with high maternal morbidity and limited perinatal benefit [96]. But again, the 
clinical criteria to determine the point where maternal and fetal conditions are stable are 
far from precise and vary widely with parameters unrelated to the disease process, such 
as individual clinician experience or availability of intensive care resources at the 
respective hospital site. There is great research interest, therefore, in identifying from the 
general population the women who ultimately are likely to develop preeclampsia so that 
measures to improve maternal and fetal outcomes are put into place in a timely manner.  
3. 3. Preeclampsia risk factors 
Many pre-pregnancy risk factors are associated with dramatically increased rates of 
preeclampsia, including hypertensive disorders, diabetes, cardiovascular disease, 
connective tissue disorders, thrombophilias and obesity [97]. In addition, limited sperm 
exposure, prior paternal conception of a preeclamptic pregnancy and assisted 
reproductive technologies are also thought to increase the risk of preeclampsia [97]. 
Furthermore, a history of preeclampsia, eclampsia or HELLP in a prior pregnancy 
increases the risk in a current pregnancy by 20 to 50 percent and up to 65 percent [97]. 
Several pregnancy-related factors also increase the risk of preeclampsia, including 
hydrops (seen in triploidy), multifetal gestation, unexplained fetal growth restriction, 
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gestational hypertension and infections [97]. Nulliparous women, for example, have rates 
of preeclampsia ranging only from two to seven percent, which is substantially lower 
than the 14 percent rate in women with twin gestations and the 17 percent rate in women 
with previous preeclampsia [78]. Although the majority of cases of preeclampsia still 
tend to occur in healthy nulliparous women, 75 percent of these cases occur after 37 
weeks gestation. Conversely, the incidence is substantially higher (20 percent) in women 
with previous preeclampsia and/or preexisting chronic hypertension, and, as the majority 
of these women deliver preterm [90,98], they represent a true high-risk population that 
needs to be targeted for future research.  
3. 4. Relevance of preeclampsia to the mother and newborn 
Maternal and fetal complications of preeclampsia are substantial and a major cause of 
maternal and fetal morbidity and mortality. Moreover, evidence suggests that the 
consequences of preeclampsia may extend beyond the immediate pregnancy and may 
predispose a patient to complications later in life [99,100,101,102]. 
 Acute maternal complications in a pregnancy complicated by preeclampsia 
include eclampsia (seizure), stroke, placental abruption, disseminated intravascular 
coagulation, HELLP syndrome, rupture of the liver, pulmonary edema, adult respiratory 
distress syndrome, acute renal failure and even death. Fetal complications include growth 
restriction, hypoxia, stillbirth and of course preterm birth with its array of long-term 
consequences resulting from prematurity, such as chronic lung disease, retinopathy of 
prematurity, cerebral palsy and mental retardation.  
 Preeclampsia also seriously impacts long-term maternal health, with 
complications such as chronic hypertension, diabetes, chronic renal failure, coronary 
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artery disease, stroke and premature death [99,100,101,102]. Consistent with the finding 
that preeclampsia is associated with key components of the metabolic syndrome, women 
with preeclampsia have in postpartum higher circulating concentrations of fasting insulin, 
cholesterol and coagulation factors compared to controls [103,104]. A genetic component 
to preeclampsia has also been proposed based on the finding that girls born in the context 
of a preeclamptic pregnancy have a higher chance of developing preeclampsia 
themselves [105]. In addition, an intergenerational study from the Walker cohort, a 
database of over 48,000 births that took place in Scotland between 1952 and 1966 and 
allows linkage of records across siblings and generations, found that infants of 
preeclamptic pregnancies had an increased risk of developing diabetes later in life, 
although birthweight seemed to be a more important determinant of such risk [106]. 
 Given the challenges in diagnosing and managing patients with preeclampsia and 
the substantial risks to the mother and fetus, better tools are needed to definitively 
diagnose patients. Improved diagnostic tools in coordination with an improved 
understanding of the etiology of preeclampsia may lead to important discoveries 
regarding effective treatments to prevent and/or treat preeclampsia.  
3. 5. Socio-economic impact of preeclampsia 
The most current 2005 database of health care costs quotes 402,539 maternal hospital 
admissions with a diagnosis of hypertensive disorders complicating pregnancy at a 
median cost of $3,472 per maternal case (compared to $2,124 for a normal delivery) 
[107]. With preeclampsia responsible for approximately 90,000 preterm births per year 
and a median hospitalization cost of $15,385 per preterm newborn case delivered 
(compared to $717 per normal term live-born), healthcare expenses attributable to 
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preeclampsia in 2005 exceeded $13 billion [107]. These estimates understate the true 
costs as they do not take into account the costs of direct medical care accrued beyond the 
initial infant hospitalization, nor do they incorporate the indirect costs of medical and 
educational interventions, disability and lost individual and family productivity. In the 
most comprehensive analysis to date on the economic cost of prematurity, the Institute of 
Medicine estimated that the societal economic burden associated with preterm birth in the 
United States in 2005 was $51,600 per infant born preterm [15].  
Much of the research focus in reducing the rate of preterm birth has been to 
search for strategies to prevent spontaneous preterm birth, despite the fact that the rate of 
spontaneous preterm birth has been steadily decreasing in the past two decades [8] while 
medically indicated preterm birth is increasing [7]. Although it remains plausible that 
prolongation of gestation might be beneficial for the neonate in selected cases of very 
preterm labor where fetal compromise and infection have been ruled out, data from 
randomized trials suggests tocolytics cannot prolong pregnancy more than 48 hours 
[108,109,110,111]. Furthermore, their use alone had no meaningful impact on neonatal 
morbidity and mortality [112,113]. The prophylactic use of 17 alpha-hydroxy-
progesterone caproate is currently advocated to reduce the rate of a subsequent preterm 
birth in women with a prior history [114,115]. Results of recent studies aimed to extend 
its use to other categories of high risk women, however, have shown the treatment to be 
ineffective in women pregnant with twins, and it failed to improve the outcome of the 
neonates delivered by mothers with short cervix [116,117]. Nevertheless, it is advocated 
that even the predicted reduction in the preterm birth rate by two percent [118] might 
render the strategy cost effective by saving approximately $2 billion annually [119] if all 
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30,000 pregnant women with a prior spontaneous preterm birth in the United States were 
universally treated with 17 alpha-hydroxy-progesterone caproate. 
We believe that strategies to reduce the rate of or prevent mandated preterm 
delivery for preeclampsia would be more efficient and cost-effective in reducing the rate 
of preterm birth than strategies aimed at preventing spontaneous etiologies. Such 
strategies should have at the forefront: 1) identification of novel biomarkers to improve 
the differential diagnosis of cases in true need of early delivery, 2) accurate prediction of 
such cases so that antenatal steroid courses can be completed, and 3) research on novel 
pathophysiologic pathways leading to preeclampsia and focused on identifying new 
therapeutic targets. The first two strategies are important because they can be 
implemented without delay in the current state of clinical practice. The potential for the 
third strategy to postpone or even prevent maternal and fetal deterioration, favoring fetal 
development in utero rather than in neonatal intensive care unit, makes its challenging 
undertaking worthwhile.  
3. 6. Pathophysiology of preeclampsia 
The etiology of preeclampsia is yet unknown, but the syndrome is known to involve 
multiple organ systems and generalized vasoconstriction, metabolic changes, endothelial 
dysfunction (thought to be induced by oxidative stress), coagulation dysfunction and 
inflammation. Compelling evidence suggests that key disturbances at the fetal-maternal 
interface play a central role in the etiology and pathogenesis of the clinical manifestations 
of this syndrome, leading to progressive deterioration of the maternal and fetal condition 
[120]. Proposed pathophysiologic mechanisms include impaired trophoblast 
differentiation and invasion, placental and endothelial dysfunction, immune 
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maladaptation to paternal antigens and an exaggerated maternal systemic inflammatory 
response characterized by aberrant lymphocyte Th1/Th2 cytokine balance 
[121,122,123,124]. 
One of the difficulties in studying preeclampsia has been to separate initiating 
events related to etiological factor(s) from those that could be attributed to compensatory 
mechanisms aimed to maintain maternal and fetal homeostasis. For instance, the increase 
in blood pressure seen in the mother may develop consequent to poor placental perfusion, 
although the reverse scenario is also plausible. In other words, both the poor placental 
invasion and trophoblast hypoxia could be secondary rather than primary events. 
Therefore, because the etiology of preeclampsia is poorly understood, interventions 
directed at risk factors or at normalizing low-end homeostatic disturbances, such as 
antihypertensives, antioxidants and low-dose aspirin, have had minimal impact in 
preventing poor outcomes related to preeclampsia and medically indicated preterm birth 
[97,125].   
Despite the various controversies on the initial trigger for preeclampsia, 
researchers seem to agree at least on two ominous pathophysiologic characteristics: 
generalized activation of the maternal endothelium and the presence of toxic humoral 
factor(s) that circulate in plasma of patients afflicted with preeclampsia and can perturb 
endothelial cell function in vitro [126]. Although experimental evidence from many 
different laboratories has repeatedly demonstrated marked alterations in cell behavior and 
metabolic processes when cultured endothelial cells or blood vessels are incubated with 
serum or plasma samples from women with preeclampsia as compared to control 
pregnant women, the search for the elusive toxemia factor has proven difficult, perhaps 
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due to its non-singular nature [127,128,129]. For instance, the factor(s) stimulating nitric 
oxide production in endothelial cells appear to be lipoprotein or lipoprotein aggregates 
and different from what stimulates prostacyclin production, which is induced by a small 
molecular weight aqueous fraction [129] that is heat and acid labile and activated by mild 
proteolytic digestion [130]. 
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4. A ROLE FOR RAGE ACTIVATION IN PRETERM BIRTH 
4. 1. RAGE activation, a link between chronic inflammation and injury 
RAGE is a multiligand transmembranar receptor and a member of the immunoglobulin 
superfamily with crucial roles in various pathophysiologic processes, including 
inflammation [131]. RAGE is present on numerous cell types, including endothelial cells, 
macrophages, neurons and smooth muscle cells. More recently, RAGE has also been 
identified in the fetal membranes and placenta [132]. RAGE was initially identified by its 
ability to engage advanced glycation end-products (AGEs). In time, however, it became 
clear that a wide range of ligands can bind to RAGE and that RAGE activation is a 
generalized feature of many chronic inflammatory conditions, including diabetes, 
rheumatoid arthritis, arteriosclerosis and Alzheimer’s disease [133,134,135]. Known 
ligands include HMGB1, S100 proteins, heat shock proteins and β-amyloid [133, 
131,134,135,136].  
 Like TLRs, RAGE is a pattern recognition receptor that is engaged by three-
dimensional structures rather than specific amino acid sequences. Expression of RAGE is 
constitutively increased during embryonal development, especially in the cerebral cortex, 
hippocampus and cerebellum, but downregulated in adults [137]. In adults, down-
regulated cells can be induced to express RAGE, however, when inflammatory mediators 
and RAGE ligands accumulate [77]. 
 Binding of a ligand to RAGE activates key signaling pathways, such as the 
proinflammatory NF-κB pathway, to promote cytokine production, including TNF, IL-6, 
and IFN-γ, and cell survival. NF-κB transactivation plays a pivotal role in parturition via 
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induction of pro-inflammatory cytokines, prostaglandins and matrix metalloproteases 
[138]. In addition, RAGE has been shown to activate the MAP-kinases ERK and p38, 
which also result in the downstream activation of NF-κB. RAGE-mediated NF-κB 
activation is unique because of its self-perpetuating and sustained nature, which 
overwhelms the auto regulatory inhibitory feedback loops [139]. An oxidant environment 
has been demonstrated to play a key role in fuelling RAGE activation, and ligand binding 
to RAGE is known to generate intracellular reactive oxygen species and consequently 
deplete antioxidant defense mechanisms [133,140,141,142]. Because RAGE-mediated 
cellular stimulation promotes increased expression of the receptor itself, RAGE functions 
as a perpetuation relay factor that propagates in a positive feedback fashion a destructive 
host response leading to a state of chronic inflammation rather than resolution.  
A number of studies have shown that RAGE signaling is abrogated by an 
endogenous soluble truncated form of the RAGE (soluble RAGE, or sRAGE), which acts 
as a decoy by binding RAGE ligands [133]. sRAGE derives from proteolytic cleavage of 
the membrane-bound RAGE [143]. The stimulus for RAGE shedding seems to involve 
HMGB1 binding to RAGE and the sheddase ADAM10 [143,144]. In patients with 
diabetes, elevated plasma sRAGE levels have been shown to act as markers of increased 
cellular RAGE expression and activation [145].  
Recent evidence from Dr. Irina A. Buhimschi’s laboratory at the Yale University 
School of Medicine has indicated that RAGE activation may play important pathogenic 
roles in preterm birth and preeclampsia [132,146,147]. In point, it has been shown that 
preeclampsia is associated with a state of RAGE activation on the maternal side 
characterized by increased maternal circulating levels of soluble RAGE [146]. This 
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occurs in contrast to fetal RAGE activation and low fetal soluble RAGE levels observed 
in inflammation-induced preterm birth [147,132]. This disparity spearheaded our search 
for putative stimuli and for implications for the opposing types of RAGE activation in the 
two major obstetrical syndromes leading to preterm birth and perinatal morbidity: intra-
amniotic infection and preeclampsia. The results of these findings are included in Section 
7 of this Thesis. 
4. 2. Particularities of RAGE activation in inflammation-induced preterm birth  
Using proteomic mapping of amniotic fluid, Dr. Buhimschi’s laboratory has found that 
one of the putative RAGE ligands, S100A12, is present in the amniotic fluid of women 
with intra-amniotic infection in direct relationship to the degree of inflammation and 
 
Figure 3. (A) Representative SELDI-TOF mass spectrometry profiles of amniotic fluid samples 
from three different women with varying degrees of intra-amniotic inflammation (MR 0: no 
inflammation; MR 2: mild inflammation; MR 3-4: severe inflammation). P3 (marked with red) 
denotes the biomarker corresponding to S100A12. (B) Survival analysis for the 131 patients, 
illustrating the shorter duration from amniocentesis-to-delivery in women with MR scores 3 or 4. 
Originally published in PLoS Med. 2007 Jan 16; 4(1):e18. Republication herein permitted by 
authors under Creative Commons Attribution License. 
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severity of histological chorioamnionitis [146,148]. Moreover, of the four proteomic 
biomarkers with diagnostic value for intra-amniotic inflammation, it was the appearance 
of the peak corresponding to S100A12 that best predicted impending preterm birth 
[149,150]. Figure 3 illustrates representative proteomic profiles of amniotic fluid from 
women with and without inflammation obtained using surface enhanced laser desorption 
ionization time-of-flight (SELDI-TOF) mass spectrometry for the four biomarkers of the 
Mass Restricted (MR) score, a composite proteomic profile with biological and clinical 
significance [149,150]. The MR score is calculated by summing the number of peaks 
identified at SELDI-TOF analysis and thus varies from 0 (no biomarkers present) to 4 (all 
four biomarkers present). In this way the proteomic information is digitized in a 
numerical variable that then can be manipulated using regular statistics. The biomarker 
peaks were determined to correspond to P1 (neutrophil defensins-2), P2 (neutrophil 
defensins-1), P3 (S100A12, calgranulin C) and P4 (S100A8, calgranulin A), all proteins 
with important roles in innate immunity. An important observation from a prospective 
study of 169 samples of amniotic fluid was that the biomarkers of the MR score appear in 
an ordered temporal sequence from P1 to P4, which corresponded biologically to the 
transition of the process of intra-amniotic inflammation from absent (M=0) to acute (MR 
1 or 2, 93% of cases represented by the presence of defensins peaks) to chronic (MR 3 or 
4). The transition from acute to chronic inflammation was rendered in all but one case of 
MR=3 by the appearance of the biomarker corresponding to S100A12 [150]. Reasoning 
that in addition to being biomarkers the proteins of the MR score may participate directly 
in modulating the intra-amniotic inflammation process and its consequent preterm birth 
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and fetal injury, our group sought to understand the pathophysiological implication of the 
observation of the elevated amniotic fluid S100A12. 
S100A12 (also known as calgranulin C) is a member of the low-molecular weight 
EF-hand S100/calgranulin family [151] known to be expressed in granulocytes [152], 
monocytes [153] and select epithelial cells [154] and that characteristically accumulates 
at sites of chronic rather than acute inflammation [155]. S100A12 protein has recently 
gained increased attention as a ligand for RAGE [131], a property that led it to be named 
ENRAGE (extracellular newly identified RAGE-binding protein) [133]. In the first study 
to assess the presence and regulation of the S100A12/RAGE axis in human pregnancy 
[132] Buhimschi’s group found that 1) S100A12 is present in amniotic fluid of women 
with intra-amniotic infection in direct relationship with the degree of inflammation and 
severity of histological chorioamnionitis and funisitis, 2) S100A12 localized primarily to 
infiltrating inflammatory cells, 3) histological chorioamnionitis was associated with 
elevated S100A12 mRNA levels in fetal membranes but not placenta, and 4) amnion 
epithelial, decidual and extravillous trophoblastic cells in fetal membranes and placenta 
are potential sites of signaling via RAGE, which is ubiquitously expressed in these cell 
types. The group thus proposed that the low levels of endogenous sRAGE earlier in 
pregnancy (less than 30 weeks) may predispose to enhanced RAGE activation in the 
event of a microbial challenge, while the excess of sRAGE later in gestation (greater than 
30 weeks) may act as a natural blocker of the NF-κB activation. This gestational age 
dependence of the inhibitor molecule sRAGE may be one potential explanation for the 
higher incidence of infection-related preterm deliveries and mostly PPROM at earlier 
gestational ages [132]. 
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In a subsequent study [147], Buhimschi’s group found significantly lower sRAGE 
in human fetuses that mounted robust inflammatory responses. Moreover, in addition to 
S100A12 and S100A8, our group found that human amniotic fluid from pregnancies with 
intra-amniotic inflammation-induced preterm birth also contain elevated levels of 
HMGB1, a prototype DAMP and well-recognized RAGE ligand. Furthermore, in an 
animal model of endotoxin-induced fetal damage and preterm birth, we determined that 
inflammation induces a significant change in expression of RAGE and HMGB1 at sites 
of tissue injury localized in vital fetal organs. These results, some of which are included 
in Section 7 of this Thesis, indicate that RAGE activation fuelled by accumulation of 
HMGB1 may be an important mediator of the antenatal cellular damage in fetuses 
delivered in the setting of inflammation-induced preterm birth. 
4. 3. Particularities of RAGE activation in preeclampsia 
The role of RAGE signaling in pregnancy-associated pathology has not been well 
studied. Recent research from Buhimschi’s laboratory showed that women with severe 
preeclampsia have increased serum and amniotic fluid levels of sRAGE as compared to 
gestational age-matched controls [146]. These findings are consistent with a state of 
RAGE pathway activation but in contrast to the findings of decreased sRAGE levels in 
fetuses exposed to a chronic state of intra-amniotic inflammation [147]. Since 
preeclampsia is known to associate with oxidative stress, Buhimschi’s group explored 
and found that sRAGE is released from amnion and maternal decidua in response to a 
free radical challenge ex vivo. In contrast, placental villous tissue (obtained at elective C-
section at term) did not secrete detectable sRAGE or respond to either an oxidative or 
inflammatory challenge with elevated sRAGE, suggesting that the source of the elevated 
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sRAGE in preeclampsia may be in the fetal membranes rather than in the placenta [146]. 
Moreover, since the cord blood sRAGE levels of fetuses born in the context of severe 
preeclampsia did not appear significantly elevated, it was reasoned that the fetus is 
probably not affected and that the preeclamptic RAGE activation is likely confined to the 
maternal compartment. Regardless of its source, however, identifying the stimulus 
responsible for the maternal RAGE activation in preeclampsia was of particular interest 
to our laboratory and my studies, the findings of which are incorporated in Section 7 of 
this Thesis. Briefly, we explored whether prototype RAGE ligands, such as advanced 
glycation end-products (AGEs) or HMGB1, are differentially expressed in relationship 
with presence or severity of preeclampsia as well level of inflammation or oxidative 
stress, two RAGE-related pathogenic pathways known to be activated in preeclampsia in 
relationship with symptom severity.  
4. 4. Excess advanced glycation end-products (AGEs) as a stimulus for RAGE  
Advanced glycation end products (AGEs) are a pleiotropic group of molecules formed 
from the nonenzymatic reaction of reducing sugars with free amino groups of proteins, 
lipids and nucleic acids. This reaction occurs often in cooking processes when sugars are 
heated together with fats or proteins (browning) and is referred to as the Maillard reaction 
after the French chemist Louis-Camille Maillard, who first described it chemically in 
1912 as part of his PhD Thesis. The reaction between sugars and amino groups was 
previously described in 1908 by two Englishmen, Walter John Skyes and Arthur R. Ling, 
who while studying beer brewing processes theorized that the amber color of the beer 
results from a chemical reaction of sugars and proteins [156]. It was Maillard, however, 
who realized the implications of the reaction for other areas, including medicine, and 
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made the insightful statement that the reaction may lead to “better utilization of sugars by 
diabetics” [157]. 
Today it is well established that AGEs also form endogenously as a byproduct of 
normal metabolism and contribute to the normal processes of aging that affect tissue 
proteins. Under certain pathologic conditions, such as diabetes, Alzheimer’s disease, 
rheumatoid arthritis, systemic lupus erythematosus or other states characterized by 
oxidative stress, the formation of AGEs occurs at an extremely accelerated rate 
[158,159]. In such situations or in renal failure, when the clearance of AGEs is impaired, 
excess AGEs deposit in various tissues, as is the case with the well known hemoglobin 
A1c in diabetes, which has been linked to diabetic vascular complications [158]. Excess 
AGEs have also been implicated in the progression of neurodegenerative diseases and 
cancers [160]. Ingesting excess food AGEs has been found to play an important role in 
the pathogenesis of AGE-related disorders as well [161]. 
Evidence suggests that the pathogenic role of accumulated AGEs is a 
consequence of their ability to stimulate RAGE, eliciting oxidative stress and 
subsequently altering gene expression in various types of cells. Furthermore, it has been 
demonstrated that excess AGEs generate auto-antibodies against the modified amino acid 
residues in an organism’s effort to clear the excess AGEs. Nε-carboxymethyl-lysine 
(CML) is a prototype AGE and a major antigenic structure in vivo that has been closely 
linked to oxidative stress and chronic inflammatory conditions via RAGE activation and 
anti-CML antibody formation [162]. CML, which was the first AGE to be identified in 
vivo, can be formed by pathways alternative to the Maillard reaction (such as auto-
oxidation). In fact, CML has received great interest in non-hyperglycemic diseases 
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characterized by oxidative stress and inflammation, such as cardiovascular hypertensive 
disorders and atherosclerosis, where it has been linked to endothelial dysfunction [163].  
Given that preeclampsia unanimously exhibits oxidative stress, inflammation and 
endothelial dysfunction in the placenta and maternal vascular system, we sought to 
determine whether elevated maternal serum AGEs could explain these pathophysiologic 
findings. Prior to our studies, one report found that CML levels appeared elevated in 
preeclamptic women compared to healthy pregnant and non-pregnant women, and 
preeclamptic placentas presented higher CML staining intensity compared to controls 
[164]. Futhermore, skin autofluorescence, a non-invasive measure of tissue AGE 
accumulation, was also increased in women recently diagnosed with preeclampsia [165]. 
Neither study, however, included a group of pregnant hypertensive but non-preeclamptic 
women to delineate whether the increased AGEs represent a primary event related to 
preeclampsia pathogenesis or secondary to hypertension. Moreover, as the renal 
clearance parameters change in pregnancy, serum CML levels would have to be 
interpreted together with the kidney’s ability to clear CML, and prior to our investigation 
no published study examined these aspects in relationship to the level of RAGE 
activation.  
Pregnancy is known to produce dramatic changes in volume and composition of 
the body fluids consistent with an increase in plasma volume of up to 40 percent and a 
dilutional fall in hematocrit and plasma albumin concentration, as well as increased renal 
blood flow and glomerular filtration rate up to 50 percent by the end of the first trimester. 
In preeclampsia, however, the rise in glomerular filtration rate observed in normal 
pregnancy is virtually absent [166]. Furthermore, the increase in urinary protein excretion 
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in preeclampsia that occurs secondary to alterations in the size and/or charge selectivity 
of the glomerular filter, increase in glomerular capillary pressure and compromise of 
proximal tubular reabsorption may also non-specifically affect blood levels of analytes 
with renal excretion [166]. Calculation of fractional excretion (clearance ratios) or 
analyte levels after correction for proteinuria, therefore, may help better elucidate 
whether any increased serum values are due to increased production or decreased 
excretion [167,168]. 
4. 5. HMGB1 as a stimulus of RAGE  
Originally described as a DNA-binding protein that stabilizes nucleosomes and facilitates 
transcription [169], HMGB1 is expressed in all cells and preferentially localized in the 
cell nucleus. Recently, HMGB1 has also been found to have extracellular roles as a 
potent cytokine and delayed mediator of inflammation. Damaged and necrotic cells 
release HMGB1 into the extracellular space, exhibiting cytokine-like activity and 
triggering inflammatory responses. In contrast, apoptotic cells retain HMGB1 within the 
intracellular space and consequently do not promote inflammation. Activated 
macrophages, mature dendritic cells and natural killer cells are able to secrete HMGB1 in 
response to injury, infection and inflammatory stimuli and, in contrast to non-immune 
cells, are protected against its toxic effects [74,75,76,77]. After it has been released in the 
extracellular space, HMGB1 engages pattern recognition receptors, such as RAGE, TLR-
2 and TLR-4, to activate innate immunity via NF-κB transactivation, thus acting as a 
prototype DAMP. 
Recently it was discovered that HMGB1 is a delayed mediator of endotoxin 
lethality [170]. Unlike TNFα, which is produced by macrophages within hours after 
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activation, HMGB1 is released for days after endotoxin exposure. Injection of 
recombinant HMGB1 into mice is lethal and causes clinical signs of sepsis and multiple 
organ failure [171]. HMGB1 detection in serum is delayed by 12 to 18 hours after peak 
levels of the classical early pro-inflammatory mediators TNFα and IL-1, and LPS, TNFα 
and IL-1 all have been demonstrated to cause extracellular release of HMGB1 [170, 171]. 
Oxidative stress is another known trigger of HMGB1 release [74].  
 To date, there has been no published systematic study of HMGB1 in pregnancy 
complications. One immunohistochemistry study examined placentas from a group of 
normal pregnancies at term compared to a group of preeclamptic women (term and 
preterm) and found that HMGB1 was present in both tissues at similar levels, although 
visually the decidua of preeclamptic women appeared more intensely stained [172]. Prior 
to our studies, there are no reports in the literature related to HMGB1 levels in 
relationship to HMGB1 in intra-amniotic infection, inflammation or processes leading to 
fetal cellular damage.  
4. 6. The S100 protein, S100B, as a stimulus for RAGE 
S100B is a member of the S100 family of proteins, calcium-binding proteins that contain 
two canonical EF-hand structural motifs [173], and is abundantly expressed in the central 
nervous system [174]. In general, relatively high concentrations of S100 proteins are 
required for activation of RAGE in responsive cells. Compared to other S100 proteins, 
S100B is unique in that it can engage RAGE in neurons at both low and high 
concentrations with divergent trophic or toxic effects. In the human brain S100B is mainly 
synthesized by astroglial cells and its physiological roles are important in regulating cell 
cycle and modulating long-term synaptic plasticity [175]. Changes in brain homeostasis 
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consistent with cell damage or cell stress trigger secretion and release of S100B in the 
extracellular space, where its action depends remarkably on its concentration [174,176]. 
At nanomolar levels S100B is neuroprotective while micromolar concentrations of 
S100B promote apoptosis and cellular damage via overproduction of reactive oxygen 
species [174]. Typically S100B is referenced as the homodimer of two S100β chains. 
Higher order S100β assemblies (hexamers, tetramers, octamers), however, have been 
observed in human brain extracts and are thought to act as high affinity extracellular 
RAGE activators through receptor multimerization, which could represent a distinct and 
higher order regulatory level of S100B’s RAGE-dependent activity aside from its 
concentration [177]. Important for neuro-inflammation is the co-release of HMGB1 with 
S100B, resulting in a shift in the effects of physiological S100B concentrations from 
homeostatic to cell damaging [178]. Thus, S100B-HMGB1-RAGE interactions may have 
important consequences during development as well as in inflammatory and oxidative 
states with a central nervous system component. 
Transgenic mice over-expressing S100B have been shown to exhibit increased 
vulnerability to perinatal hypoxic-ischemic injury, with heightened glial activation, 
neuro-inflammation and increased mortality [179]. S100B increases in cerebrospinal fluid 
(CSF) of infants affected by perinatal asphyxia and post-hemorrhagic brain damage [180, 
181]. In this setting, S100B levels in CSF correlate with the extent of brain lesions, long-
term neurological outcome and neurological impairment or death at one year of age 
[180,181]. Under the assumption that S100B is released from the damaged tissue during 
active brain injury, previous studies attempted to determine the usefulness of measuring 
S100B in blood as a predictor of hypoxic-ischemic encephalopathy [182]. Increased 
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concentrations of S100B have been detected 48 to 72 hours before clinical, laboratory or 
ultrasound signs of cerebral bleeding in preterm infants [183]. An animal model 
demonstrated that intravenous endotoxin administration to pregnant sheep caused fetal 
white matter damage, inflammation and an increase in S100B release in fetal blood at one 
and three hours after administration [184]. The studies exploring the relationships 
between S100B and fetal inflammation, however, are limited. One report examined the 
levels of S100B in amniotic fluid and found that although intra-amniotic infection elevated 
the S100B concentration, the elevation appeared unrelated to neonatal outcome and thus 
concluded that amniotic fluid S100B may reflect intra-amniotic inflammation but not 
necessarily fetal neurological damage [185]. An alternative explanation may be that tissues 
other than the fetal brain also contribute to the pool of amniotic fluid S100B, making it 
difficult to determine which portion of S100B is of fetal neural origin. No prior study has 
attempted to determine relationships between severity of intrauterine inflammation and 
release of S100B in fetal circulation or to correlate levels of S100B to fetal levels of other 
late-phase cytokines (e.g., HMGB1) or to indicators of morbidity in premature newborns. 
As detailed in Section 7 of this Thesis, we found that fetal S100B levels are elevated in 
relation to cord blood HMGB1 in intrauterine infection. 
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5. STATEMENT OF PURPOSE 
The hypothesis that stays at the basis of the research presented in this Thesis is that the 
difference in the types of RAGE activation that occur preterm fetuses born in the context 
of intrauterine infection and inflammation and in women with preeclampsia is driven by 
differences in the stimuli that engage RAGE in these two very different clinical scenarios. 
If this hypothesis holds true, agents targeted against RAGE pathway activation either by 
binding the excessive specific stimuli or blocking downstream RAGE signaling elements 
may have potential therapeutic value for preventing occurrence or exacerbation of 
preeclampsia symptoms or fetal damage. A detailed knowledge of the nature, source and 
levels of molecules capable of activating the maternal or fetal RAGE axis and resulting in 
pregnancy complications leading to spontaneous or indicated preterm birth is, therefore, 
necessary and the purpose of the research presented herein.  
5. 1. Specific Aims 
Specific Aim 1. Identify putative stimuli driving fetal RAGE activation in pregnancies 
complicated by preterm birth and intra-amniotic inflammation.  
To achieve this aim in case control study design our objectives were as follows: 
a) To determine the relationships between severity of intra-amniotic inflammation and 
amniotic fluid levels of HMGB1. 
b) To determine the relationships between severity of fetal inflammation (as reflected by 
cord blood levels of the acute phase cytokine IL-6) and fetal cord blood HMGB1 and 
S100B concentrations.  
c) To determine the relationships between cord blood levels of the late phase cytokine 
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HMGB1 and S100B concentration.  
d) To determine levels and patterns of HMGB1 expression in placenta, amniochorion and 
umbilical cord in relationship to histological evidence of chorioamnionitis and funisitis.  
e) To examine the pattern of HMGB1 release in response to endotoxin challenge ex vivo.  
 
Specific Aim 2. Identify putative stimuli driving RAGE activation in pregnancies 
complicated by preeclampsia.  
To achieve this aim in case control study design our objectives were as follows: 
a) To determine whether blood and urine levels of conventional RAGE ligands, such as 
the prototype advanced glycation end-product Nε-carboxymethyl-lysine (CML), and anti-
CML auto-antibodies, a reflection of excess CML antigenicity, are elevated in women 
with severe preterm preeclampsia as compared to gestational age matched controls. 
b) To determine whether blood and urine levels of HMGB1 (amphoterin) are elevated in 
women with severe preterm preeclampsia as compared to gestational age matched 
controls.  
c) To determine whether fractional excretion indicators of CML, anti-CML auto-
antibodies and HMGB1 are altered in women with severe preeclampsia and gestational 
age matched controls. 
d) To determine whether significant changes in either blood or urine levels or fractional 
excretion indicators of the above analytes are either gestational age- or hypertension-
rather than preeclampsia-related and could be thus deemed nonspecific. The above results 
were therefore interpreted relative to those of pregnant normal women at term or women 
with chronic hypertension who did not develop preeclampsia.  
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e) To determine the relationships between levels of HMGB1, CML and anti-CML auto-
antibodies and levels of systemic inflammation or RAGE activation as reflected by 
maternal blood concentrations of TNFα and sRAGE, respectively. 
f) To determine levels and cellular sites of expression of CML and HMGB1 in placenta 
and amniochorion of women with severe preterm preeclampsia as compared to non-
preeclamptic women with either a term elective C-section delivery or spontaneous 
idiopathic preterm birth (i.e. absence of clinical or histological evidence of infection, 
inflammation or abruption). 
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6. METHODS 
All procedures and experiments described in this section were conducted by me unless 
otherwise noted.  
6.1. Patient population, biological samples, clinical definitions and clinical laboratory 
analyses. 
Biological samples (maternal blood, maternal urine, amniotic fluid and cord blood) were 
collected from women recruited at Yale-New Haven Hospital (YNHH) following 
admission to Labor and Birth or assessment in high- or low-risk antepartum units. Patient 
enrollment was performed depending on clinical presentation in two prospective cohorts, 
“rule-out preeclampsia” or “rule-out preterm birth,” pursuant to protocols approved by 
the Human Investigation Committee of Yale University. For both enrollment cohorts 
patients were followed until delivery or discharge, and medical record data was entered 
prospectively in a de-identified perinatal research database that links the medical record 
information (including laboratory results and neonatal assessments for the newborns 
admitted to Newborn Special Care Unit) with the codes on the stored biological samples. 
This database is updated continuously by specific research staff. Patients included in the 
analyses herein were recruited from May 2004 to October 2007. The decision to 
recommend admission, any clinically indicated laboratory tests or procedures, including 
amniocentesis or delivery of the fetus, was made by the primary physician, independent 
of the research protocols.  Patient recruitment, sample processing and abstraction of data 
from medical records were performed by medical or research staff as appropriate and 
were independent of me.  
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 After collection, samples for research were transported to the laboratory where they 
were spun at 3000g and 4ºC for 20 minutes, aliquoted in polypropylene cryotubes and 
stored at -80ºC until analysis. 
Maternal serum and urine samples were collected contemporaneously as 
previously described [167,168] and selected based on availability from women originally 
enrolled in the “rule-out preeclampsia cohort.” The urine sample (5-10 mL) was 
collected in a sterile container (“clean catch” method or bladder catheterization if 
performed for clinical indications). Blood samples were collected by venipuncture prior 
to intravenous administration of fluids and allowed to clot.   
 Gestational age was established based on last menstrual period and/or early 
ultrasound evaluations (less than 20 weeks of gestation) in all cases [186]. Severe 
preeclampsia was defined based on the American College of Obstetricians and 
Gynecologists criteria [187] as gestational age greater than 20 weeks, blood pressure of 
160 mm Hg systolic or higher or 110 mm Hg diastolic or higher on 2 occasions at least 6 
hours apart, and/or proteinuria of at least 5 g in a 24-hour urine specimen or 3+ or greater 
on 2 random urine samples collected at least 4 hours apart [187]. Other elements of the 
diagnosis included: intrauterine growth restriction (less than 10th percentile), cerebral or 
visual disturbances (headache, visual changes), epigastric or right upper-quadrant pain, 
pulmonary edema or cyanosis, oliguria (urinary output less than 500 mL in 24 hours) or 
elements of HELLP syndrome, such as impaired liver function tests (greater than two 
times normal) and/or thrombocytopenia (less than 100,000 cells/µL). Chronic 
hypertension was defined as a sustained elevation in blood pressure greater than 140/90 
mmHg before pregnancy or before 20 weeks gestation. Since preeclampsia is a 
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progressing disease and by definition a clinical diagnosis for which no acceptable gold 
standard is yet available, our data was also analyzed based on an outcome measure (the 
need for delivery for preeclampsia) rather than solely by clinical classification at 
enrollment. Similar to our prior study, we reasoned that an indication for mandated 
delivery belongs to a team, is the last management resort when all other strategies have 
failed and its resulting outcome is final, cannot be revoked and is thus less subject to bias 
[188]. 
 Selection of samples from the biological repository and assignment to either control 
or study groups for the purpose of the analyses included herein was based on clinical 
diagnoses at sample collection and/or outcome and was done not by me and prior to my 
evaluation of analytes of interest or statistical analysis. None of the originally selected 
samples was excluded from the final analysis. 
 Amniotic fluid was collected from women pregnant with singletons originally 
enrolled in the “preterm birth cohort” who had a clinically indicated amniocentesis to 
rule-out infection as deemed necessary by managing physicians and independent of the 
research protocol. Amniotic fluid was collected by ultrasound-guided amniocentesis, and 
each woman was followed prospectively until delivery.  
 Eligible women had a gestational age at delivery greater than or equal to 23.1 
weeks, preterm labor contractions refractory to tocolysis, preterm premature rupture of 
membranes (PPROM) or advanced cervical dilatation (greater than 3 cm). Exclusion 
criteria were the presence of anhydramnios, human immunodeficiency or hepatitis viral 
infections, congenital anomalies, abnormal karyotype or any known maternal medical 
conditions. Preterm labor was defined as the presence of regular uterine contractions and 
 45 
documented cervical effacement and/or dilatation in patients less than 37 weeks of 
gestation. PPROM was confirmed by vaginal amniotic fluid pooling, nitrazine, ferning or 
an amniocentesis-dye positive test. Corticosteroids and antibiotics were recommended as 
clinically indicated. The neonatology resuscitation team was present at the time of 
delivery for all neonates. 
Clinical laboratory tests performed for the purpose of diagnosing infection or 
inflammation included glucose, lactate dehydrogenase (LDH), white blood cell (WBC) 
count, Gram stain and amniotic fluid cultures. For clinical management, an amniotic fluid 
glucose cut-off of less than or equal to 15 mg/dL and LDH levels greater than or equal to 
419 U/L were considered suggestive of intra-amniotic infection [189,190]. 
Amniotic fluid cultures were performed by the microbiological laboratory. 
Briefly, the fluid was centrifuged and the sediment re-suspended in 0.25 ml of 
supernatant and cultured for aerobic bacteria, including Ureaplasma and Mycoplasma 
spp, using laboratory media such as Chocolate, Martin Lewis, MacConkey, Azido 
benzoic acid, Thioglycollate, Bacteroides Bile Esculin/Laked Blood Kanamycin 
Vancomycin (BBE/LKV), Columbia CNA agar, Ureaplasma broth and agar. In addition, 
amniotic fluid was cultured in an anaerobic chamber (Forma Anaerobic System, Thermo 
Electron Co, Waltham, MA) at 37ºC. The results of the microbiological tests were 
available for case management and were reported as final after five days of culturing. 
Presumptive bacterial identification was based on standard microbiological criteria of 
colonial morphology, medium reaction, Gram stain and the use of a VITEK 2 automated 
card system (bioMérieux, Hazelwood, MO, http://www.biomerieux-usa.com) for 
bacterial identification based on biochemical tests and antibiotic susceptibility. Amniotic 
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fluid not used for clinical purposes was transported to the research laboratory and 
processed as described earlier.  
In addition to the amniotic fluid from the women enrolled in the “preterm birth 
cohort,” we analyzed two groups of normal pregnant women with either early gestational 
age (2nd trimester) amniocentesis to rule out chromosomal abnormalities or near-term (3rd 
trimester) amniocentesis for lung maturity testing. These two groups of women represent 
virtually the only ethically acceptable circumstances to retrieve amniotic fluid from 
women without clinical symptoms of preterm birth and are necessary to include in 
analyses when testing for potential gestational age regulation of sought analytes.  
Cord blood specimens were obtained for clinical assessment of the fetal acid-base 
status at birth and/or research purposes. Within 10 minutes of delivery, cord blood 
samples (umbilical artery and vein) were collected in pre-heparinized 1 cc. syringes, 
capped and transported to the laboratory. The acid-base status was determined with the 
ABL 800 FLEX blood gas analyzer (Radiometer Medical A/S, Denmark). Umbilical cord 
blood for research was obtained by aseptic puncture of the clamped umbilical vein, 
allowed to clot, centrifuged as described above and serum aliquoted in sterile 
polypropylene tubes and stored at –800C. 
Histological evaluation of the placenta is routinely performed for all preterm birth 
cases at Yale-New Haven Hospital by staff affiliated with Department of Pathology. 
Hematoxylin and eosin stained sections of extraplacental membranes (amnion and 
chorio-decidua), chorionic plate, chorio-decidua and umbilical cord were examined 
systematically for inflammation. Three histological stages of chorioamnionitis [191] 
(stage I: intervillositis, stage II: chorionic inflammation, and stage III: full-thickness 
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inflammation of both chorion and amnion) were complemented by the described 
histological grading system derived by Salafia et al., which includes four grades of 
inflammation of the amnion, chorio-decidua and umbilical cord [192]. 
6. 2. Evaluation of presence and severity of intra-amniotic inflammation by SELDI-
TOF mass spectrometry and Mass Restricted (MR) scoring 
Evaluation of amniotic fluid samples by mass spectrometry for determination of the MR 
score was conducted by laboratory personnel other than me. The method for generation 
of the MR score has been previously described [23,149,150]. The MR score ranges from 
0 to 4, depending upon the presence or absence of each of the four protein biomarkers 
[149,150]. A value of 1 was assigned if a biomarker peak was present and 0 if absent. 
Based on our previous results, we stratified the study population based on the severity of 
inflammation (MR 0: no inflammation; MR 1-2: minimal inflammation; MR 3-4: severe 
inflammation) [150].  
6. 3. Immunoassay procedures 
ELISA for CML. 50 µL of undiluted urine samples and serum samples diluted 1:4 were 
mixed with 50 µL anti-CML-adduct monoclonal antibody and plated into wells pre-
coated with CML-BSA (Circulex, MBL International, Woburn, MA) and incubated for 
one hour at room temperature. After washing and a one hour incubation with an HRP 
conjugated polyclonal antibody specific for mouse IgG, plates were washed, and 
substrate solution was added to the wells, and color development was allowed to proceed 
for 15 minutes, at which time stop solution was added and the plates read at 450nm with 
background correction at 650 nm using a VERSAmaxTM microplate reader with Softmax 
 48 
Pro 3.1.1 software (Molecular Devices, Sunnyvale, CA). The minimum detectable 
concentrations reported by manufacturers and validated in our laboratory is 0.13 ng/mL. 
ELISA for anti-CML antibody. 50 µL of undiluted urine samples and serum samples 
diluted 1:10 were plated into wells pre-coated with CML-BSA or BSA (Circulex, MBL 
International, Woburn, MA) and incubated for one hour at room temperature. Plates were 
washed and incubated for one hour with an HRP conjugated polyclonal antibody specific 
for rat IgG. Plates were washed, and substrate solution was added to the wells, and color 
development was allowed to proceed for 15 minutes, at which time stop solution was 
added and the plates read at 450nm using a microplate reader. The readings from the 
BSA-coated plate were subtracted from the readings from the CML-BSA-coated plate. 
ELISA for HMGB1. 10 µL of urine, maternal serum, amniotic fluid or cord blood serum 
samples were plated into wells pre-coated with a polyclonal antibody specific for 
HMGB1 (Shino-Test, Kanagawa, Japan) and incubated for 22 hours at 37°C. Plates were 
washed and incubated for 2 hours with a POD-conjugate anti-HMGB1,2 monoclonal 
antibody. After washing, substrate solution was added to the wells, and color 
development was allowed to proceed for 30 minutes, at which time stop solution was 
added and the plates read as described above. The minimum detectable concentration is 1 
ng/mL. 
ELISA for S100B. 100 µL of cord blood serum samples diluted 1:4 with sample dilution 
buffer were plated into wells pre-coated with polyclonal anti-cow S100B antibody 
(BioVendor, Candler, NC) and incubated for 90 minutes at room temperature. Plates 
were washed, and, after a 90 minute incubation with a monoclonal anti-human S100B 
antibody labeled with HRP and another wash, substrate solution was added to the wells, 
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and color development was allowed to proceed for 15 minutes, at which time stop 
solution was added and the plates read at 450nm using a microplate reader. The minimum 
detectable concentration was 20 pg/mL. 
ELISA for sRAGE. 50 µL of undiluted maternal serum samples were plated into wells 
pre-coated with a monoclonal antibody specific for RAGE (R&D Systems, Minneapolis, 
MN) and incubated for 2 hours at room temperature. Plates were washed then incubated 
for 2 hours with an enzyme-linked polyclonal antibody specific for the extracellular 
domain of RAGE. Plates were washed, and substrate solution was added to the wells, and 
color development was allowed to proceed for 30 minutes, at which time stop solution 
was added and the plates read at 450nm using a microplate reader. The minimum 
detectable concentration was 4 pg/mL.  
ELISA for TNFα . 200 µL of undiluted maternal serum samples were plated into wells 
pre-coated with a polyclonal antibody specific for mouse TNFα (R&D Systems, 
Minneapolis, MN) and incubated for 3 hours at room temperature. After washing and a 2-
hour incubation with an enzyme-linked polyclonal antibody specific for mouse TNFα, 
plates were washed, and substrate solution was added to the wells and incubated for one 
hour. Amplifier solution was added, and color development was allowed to proceed for 
30 minutes, at which time stop solution was added and the plates read at 450nm using a 
microplate reader. This assay detects the total amount of TNFα in the sample composed 
of free TNFα and that bound to soluble receptors. The mean minimal detectable 
concentration in the assays for TNFα reported by the manufacturer was 0.106 pg/mL. The 
intra- and inter-assay coefficients of variation were <3.1% and 7.1%, respectively. 
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ELISA for IL-6. Immunoassays for human IL-6 (Pierce-Endogen, Rockford, IL) was 
performed on amniotic fluid or cord blood in duplicate according to manufacturer’s 
instructions by laboratory research staff excluding me. The minimal detectable 
concentration was 1 pg/mL and the inter- and intra-assay coefficients of variation <10%. 
Samples were diluted appropriately to assure that the final values fall inside the standard 
curve and are interpolated rather then extrapolated. 
6. 4. Immunohistochemical procedures and Western blotting 
Five µm paraffin sections were deparaffinized in xylene and rehydrated with graded 
ethanol to potassium-phosphate-buffered saline solution, pH 7.2. Following antigen 
retrieval with citrate buffer (for AGEs) or basic solution buffer pH 10 (for HMGB1), the 
sections were pretreated with 1% hydrogen peroxide for 15 minutes followed by one-
hour incubation in 5% donkey serum. The sections were then incubated overnight at 4°C 
with a primary antibody. Detection was performed with biotinylated donkey anti-rabbit or 
goat anti-mouse IgG (Jackson ImmunoResearch, West Grove, PA, 1:600 dilution) as 
appropriate followed by avidin-biotin staining (Vectastain Elite ABC, Vector 
Laboratories, Burlingame, CA) and incubated with 3,3´-diaminobenzidine/nickel sulfate 
as chromogen solution. Specificity of staining was confirmed by omitting the primary 
antibodies. Specific staining was evaluated semi-quantitatively in a blinded fashion by 
examining six fields per slide and subjectively scoring on a scale from 0 (no staining) to 5 
(intense blue-black staining) the intensity of the chromogen deposited in the amnion 
epithelium, chorio-decidua, placental villous trophoblast, stromal and endothelial cells. 
Slides stained immunohistochemically purposefully were not counterstained so that 
morphological changes were hidden to the examiner. For illustration purposes select 
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sections were developed using Vector NovaRed (Vector) chromogen and were 
counterstained with hematoxylin.  
 Primary antibodies used for immunohistochemistry included anti-AGE antibody 
(Clone 6D12, CosmoBio, Tokyo Japan, 1:8000 dilution), rabbit polyclonal anti-HMGB1 
antibodies (Shino-Test, Kanagawa, Japan 1:1000 dilution) and goat polyclonal anti-
RAGE (R&D Systems, 1:100 dilution).  A substantial amount of time was spent 
identifying a specific anti-HMGB1 antibody. Other HMGB1 antibodies (obtained from 
Abcam, Boston, MA or from Millipore, Billerica, MA) were rejected by us based on 
concerns regarding specificity at Western blot analysis. The Shino-Test antibody was 
determined to be the only antibody specific for HMGB1 and had to be shipped from 
Japan, requiring USDA approval for importation.  
 Western blot for HMGB1 was necessary to confirm antibody specificity as 
described above. Gel electrophoresis was carried out on 10% SDS-PAGE gels using a 
BioRad Miniprotean II (Bio-Rad, Richmond, CA) gel apparatus. Ten microliters of 
amniotic fluid were diluted 1:2 volume/volume with electrophoresis sample buffer 
(BioRad, Richmond, CA) and reduced by boiling for 5 minutes. After electrophoretic 
transfer to a PVDF membrane (BioRad) at 100 V for 60 minutes, blots were incubated in 
3% hydrogen peroxide for 15 minutes then blocked with 5% milk and incubated 
overnight at 4°C with different rabbit anti-HMGB1 primary antibodies diluted 1:500 or 
1:1000. Blots were incubated with conjugated F(ab′)2 goat anti-rabbit IgG 1:1000 in 5% 
milk as secondary antibody followed by streptavidin-biotinylated HRP 1:8000. Blots 
were subsequently subjected to ECL using a Western blotting detection system 
(Amersham, Arlington Heights, IL). Autoradiography film was applied to the blot until 
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satisfactory exposure was achieved. Antibody specificity was confirmed by omitting the 
primary antibody.  
6. 5. Urine and serum protein, creatinine quantification and calculations of fractional 
excretion indicators 
For total protein measurements, urine or maternal serum samples were diluted 1:12 or 
1:60, respectively, with deionized water and 10 µL of the diluted sample plated in 
duplicate. 200 µL of 1:50 bicinchoninic acid reagent mixture (BCA protein assay, 
Thermo Scientific, Rockford, IL) was added and incubated 20 minutes at 37°C then read 
at 500nm using a microplate reader against human serum albumin standards. 
For creatinine measurements, urine samples were diluted 1:100 and serum 
samples 1:8 with picric acid (Stanbio Laboratory, http://www.stanbio.com) and spun at 
12,000 rpm for 30 minutes. 1:4 dilutions of 3% NaOH and sample supernatant were 
plated in duplicate and incubated at room temperature for 10 minutes then read at 500 nm 
using a microplate reader against standard curves derived from known creatinine 
concentrations. 
Fractional excretion indicators (clearance ratios) were calculated using the 
formula: (urine/plasma analyte concentration) ÷ (urine/plasma creatinine concentration) x 
100. The fractional excretion of a substance represents the proportion of the substance 
excreted in the urine compared to that filtered by the glomeruli and is generally reported 
relative to creatinine clearance since creatinine is neither reabsorbed nor significantly 
secreted.  
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6. 6. Placental explant experiments  
Placentas were obtained from healthy women without any significant past medical 
history undergoing scheduled, elective cesarean delivery in the absence of labor (GA: 38-
40 wks). Indications for abdominal delivery included elective repeat or primary cesarean 
delivery for fetal malpresentation (e.g., frank breech). No patient had abnormal 
placentation (placenta previa, abruption).  All infants were appropriately grown for 
gestational age and had reassuring fetal heart rate patterns prior to surgery.  Placental 
cotyledons from the central part of the placenta and amniochorion at distance from the 
membrane rupture site were removed under sterile conditions within 30 minutes of 
delivery and dissected in a Petri dish into pieces of similar weight and washed thoroughly 
with ice-cold saline. Four pieces (approximately 100 mg wet weight) were cultured freely 
suspended in 24-well plates in 1.5 mL RPMI 1640 medium (Gibco, Grand Island, NY) 
containing 100 U/mL penicillin and 100 µg/mL streptomycin (Gibco). Cultures were 
maintained at 37°C in a humidified gas mixture of 5% CO2-95% air in the presence and 
absence of 1 µg/mL lipopolysaccharide from E. Coli (LPS). After 18 hours of incubation, 
the supernatants were collected, centrifuged to remove cellular debris and stored at –
80ºC. The incubated tissue was immediately homogenized in 1 mL cell extraction buffer 
(20-mmol/L Tris-HCl, 150-mmol/L NaCl, 1% Triton X-100, 1-mmol/L 
phenylmethylsulfonyl fluoride, and Complete protease inhibitor cocktail [Roche, 
Indianapolis, IN]). Specimens were spun at 1000 g at 4ºC for 15 minutes and protein 
quantification in incubated tissue performed using the BCA protein assay as described 
above. The analytes’ explant medium concentration was normalized to total protein in 
tissue extract to correct for variations in tissue incubated per each well. For each 
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experimental condition, values were derived by averaging normalized values from 
duplicate wells either without (untreated) or with LPS. Values were further interpreted as 
fold change from the untreated level. All chemicals were from Sigma Chemical Co. (St 
Louis, MO) unless otherwise specified. The time of incubation (18 hours) was selected to 
assure tissue viability as assessed by a non-significant change in release of the 
intracellular enzyme LDH into the incubation medium LDH activity was measured using 
LDH Liqui-UV® Assay (Stanbio, Boerne, TX).  
 The explant experiments were set up by laboratory personnel other than me. I 
analyzed the stored medium for level of HMGB1. 
6. 7. Statistical analysis 
Data were tested for normality using the Kolmogorov-Smirnov test and reported as mean 
and standard error or median and ranges, depending on the type of data distribution. 
Comparisons between two groups were performed using Student t tests or Mann-Whitney 
rank-sum tests, as appropriate. Multiple comparison procedures were performed using 
one-way or Kruskal-Wallis analysis of variance (ANOVA) followed by Student-
Newman-Keuls or Dunn’s post-hoc comparisons, as appropriate. Relationships between 
variables (correlations) were explored using Pearson’s product moment or Spearman’s 
rank-order correlations. Comparison between correlations was achieved based on z 
statistic. Multivariate linear analysis was performed using a stepwise model with 
variables eliminated based on P>0.1. MedCalc (Broekstraat, Belgium) or SigmaStat 2.03 
(Systat Inc. Chicago, IL) statistical softwares were used as aids for analysis. A P<0.05 
was judged to denote statistical significance. 
 For Specific Aim 1, sample size calculations were based on our prior data with IL-6 
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and severity of inflammation by the MR score [150]. It was estimated that 28 women in 
each group would be necessary to detect differences of 85 percent of the standard 
deviation in a 3 group ANOVA. For Specific Aim 2, sample size calculations were based 
on our prior data of serum levels of TNFα [168]. It was estimated that 27 patients in each 
group would be necessary to detect differences of 78 percent of the standard deviation. 
Additional enrolled subjects will facilitate a finer comparison between groups required to 
account for confounders and possible effect modifiers. 
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7. RESULTS 
7. 1. Specific Aim 1. Identify putative stimuli driving fetal RAGE activation in 
pregnancies complicated by preterm birth and intra-amniotic inflammation 
HMGB1 levels are increased in amniotic fluid of women with intra-amniotic 
inflammation and preterm birth, and the source may be the damaged fetal membranes. 
We first asked the question whether amniotic fluid HMGB1 concentration exhibits 
gestational age regulation in the absence of infection or inflammation. For this purpose, 
we analyzed only amniotic fluid from 
women with normal outcomes who had an 
amniocentesis for either genetic indications 
(n=25), lung maturity (n=25) or suspicion 
of intra-amniotic infection that was ruled 
out and who eventually delivered at term 
(n=25). We found that although detectable 
by immunoassay the amniotic fluid 
HMGB1 concentration did not vary 
significantly across gestation (one-way ANOVA P=0.400; Figure 4). 
To provide evidence that HMGB1, a prototype DAMP, is a key component of the 
process of intra-amniotic inflammation, we evaluated its levels in 132 samples of 
amniotic fluid retrieved from women whose pregnancies were complicated by preterm 
birth, had a clinically indicated amniocentesis to rule out infection and/or inflammation 
and resulted in a newborn admitted to the Newborn Special Care Unit. The median 
 
Figure 4: Amniotic fluid (AF) HMGB1 levels 
in women with normal outcomes per 
gestational age intervals ranging from 15 
weeks to term. The number of cases in each 
group is shown inside each column. 
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gestational age at amniocentesis was 29 [range: 18-34] weeks and at delivery was 30 [23-
34] weeks. Thirty-one percent of the newborns had a birthweight less than 1,000 grams, 
and 58 percent were less than 1,500 grams, illustrating the clinical relevance of this 
prospective cohort. We determined that women with severe intra-amniotic inflammation 
by proteomic analysis (MR 3-4) had significantly increased amniotic fluid HMGB1 
concentration compared to women with absent and mild inflammation  (Kruskall Wallis 
ANOVA P<0.001; Figure 5A). There was a direct and significant correlation of amniotic 
fluid HMGB1 to severity of intra-amniotic inflammation by MR score (P<0.001). In 
multivariate regression analysis amniotic fluid HMGB1 levels were predicted by the 
combination of an MR 3-4 and low amniotic fluid sRAGE inhibitor concentration, 
independent of gestational age at amniocentesis (P<0.001) or membrane status (ruptured 
or intact). Amniotic fluid HMGB1 also correlated significantly with amniotic IL-6 levels 
(R=0.702; P<0.001; Figure 5B).  
 
 
Figure 5: (A) HMGB1 levels in amniotic fluid (AF) of women with preterm birth (GA at delivery 
30 [23-34] wks, n=132) and absent (MR 0), mild (MR 1-2) or severe (MR 3-4) intra-amniotic 
inflammation (IAI); (B) Relationship of amniotic fluid acute phase cytokine (IL-6) to the late 
phase cytokine (HMGB1) in the same patient population. 
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We next sought to determine the source of amniotic fluid HMGB1 in pregnancies 
complicated by severe intra-amniotic inflammation. By immunohistochemistry we found 
that HMGB1 was highly expressed in fetal membranes and cord vessels and even more 
so in women with severe intra-amniotic inflammation (Figure 6). HMGB1 staining was 
particularly intense in necrotic choriodecidual areas. Placental villi had low HMGB1 
expression irrespective of inflammatory status (not shown).  
Figure. 6: HMGB1 staining in fetal membranes (a & b) and umbilical cord (c) in a patient with 
preterm birth and no inflammation (MR=0) as compared to a patient with severe intra-amniotic  
inflammation (MR 3-4), histological chorioamnionitis (b) and funisitis (d & e). Note the intense 
positive staining in necrotic zones of chorio-decidua (b: arrowheads). Bar: 50 µm (a & b) or  25 µm  





Figure 7: HMGB1 (a) and RAGE (b) staining in fetal membranes in a patient with preterm birth, 
severe intra-amniotic inflammation and necrotizing chorioamnionitis. (c) Negative control slide 
with omitted primary antibody. Note the intense positive staining of both HMGB1 and RAGE in 
the amnion. Bar: 50 µm. Chromogen: (a) Vector NovaRed and Hematoxylin counterstain; (b & c) 
Ni-DAB, no counterstain. 
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Importantly, we observed that staining for the RAGE receptor in amniotic 
membranes of women with histological chorioamnionitis localizes to the same cellular 
injury areas as HMGB1 (Figure 7), suggesting that the HMGB1-RAGE axis may play a 
role in the damage of the amniochorion in the context of intra-amniotic inflammation.  
HMGB1 is released by human fetal membranes ex vivo in response to endotoxin and 
oxidative stress. 
To further determine whether the amniochorion contributes to the amniotic fluid pool of 
HMGB1 as a source or whether the highly hydrophobic HMGB1 formed elsewhere 
simply infiltrates the damaged amnion and deposits within the chorio-decidua, we 
challenged explants of either human fetal membranes or placental villous tissue obtained 
from elective Cesearean sections at term (n=4) with endotoxin ex vivo (LPS, 1 mg/mL). 
We observed a significant elevation in HMGB1 released in amniochorion medium 
(Figure 8, P=0.008), while release by the placental villous explants remained virtually 
unchanged (not shown, P>0.05). 
 
 
Figure 8: (A) HMGB1 release was 
measured by ELISA in the medium of 
amniochorion explants at 18 hours of 
incubation. Data was normalized for 
total protein in the incubated tissue. 
Tissues were obtained under sterile 
conditions from 4 women undergoing 
elective C-sections at term. Statistical 






Cord blood HMGB1 levels do not correlate with the extent of intra-amniotic 
inflammation but rather with the extent of fetal inflammation and S100B. 
We next sought to determine whether the level of intra-amniotic inflammation and amniotic 
fluid HMGB1 translate into an increased HMGB1 concentration in umbilical cord blood. For 
this purpose we analyzed available cord blood samples of newborns of mothers where we 
also measured amniotic fluid HMGB1 (n=121). Interestingly, we did not determine that cord 
 
Figure 9: (A) Relationships of cord blood HMGB1 with amniotic fluid levels of the acute phase 
cytokine IL-6 and (B) amniotic fluid HMGB1. (C) Relationships of cord blood HMGB1 to fetal 
inflammatory status as assessed by cord blood levels of IL-6. (D) Relationship of cord blood 
HMGB1 and cord blood levels of S100B, another DAMP. 
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blood HMGB1 levels are impacted by amniotic fluid inflammation as assessed either by the 
MR score (P=0.232) or by levels of amniotic fluid IL-6 (Figure 9A). Cord blood HMGB1 
also did not correlate with amniotic fluid HMGB1 (Figure 9B). This lack of significant 
relationships maintained even when data was analyzed in multivariate analysis and other 
parameters were included in the model (gestational age, severity of histological 
chorioamnionitis, funisitis, status of the membranes and interval amniocentesis-to-delivery). 
HMGB1 level in cord blood of preterm newborns was, however, significantly correlated with 
the level of fetal inflammation, as determined by cord blood IL-6 (Figure 9C) and highly 
correlated with cord levels of S100B protein (Figure 9D), the astroglial-derived DAMP. Cord 
blood HMGB1 level was the sole predictor of elevated S100B protein, independent of 
gestational age at delivery, histological chorioamnionitis, PPROM, race or cord blood IL-6 
level (F-ratio 108.6, P<0.0001). Importantly, 
S100B did not vary significantly (P>0.05) with 
any other maternal or fetal variable tested 
except for the cord level of HMGB1.  
Our data shows that cord blood 
sRAGE also increases with gestational age 
(R=0.42, P=0.007). Importantly, cord blood 
HMGB1 levels are significantly higher 
compared to both sRAGE and S100B, 
identifying HMGB1 as an important signaling 
molecule for the fetus (Figure 10). 
 
Figure 10: Levels of RAGE agonists 
HMGB1 and S100B and antagonist sRAGE 
in cord blood of 37 preterm newborns with no 
evidence of intra-amniotic infection, absent 
intra-amniotic inflammation (MR 0) and no 
histological chorioamnionitis. 
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In summary, these findings suggest that amniotic fluid HMGB1, likely a reflection of 
the damaged amniochorion in the context of severe intra-amniotic fluid inflammation, does 
not directly translate into an elevation in fetal HMGB1. Another checkpoint therefore must 
exist to prevent the accumulation of amniotic fluid HMGB1 in the fetus, perhaps amniotic 
fluid sRAGE. Alternatively, unlike the amniochorion, the fetus may have the ability to 
metabolize HMGB1, thus controlling the HMGB1 level within the fetal compartment 
independent from that within the amniotic cavity. 
7. 2. Specific Aim 2. Identify putative stimuli driving RAGE activation in pregnancies 
complicated by preeclampsia 
RAGE activation in severe preeclampsia occurs independent of levels of advanced 
glycation end-products (AGEs).  
We first searched for the presence of the prototype AGE Nε-carboxymethyl-lysine 
(CML) and CML auto-antibodies in a case control study of time-matched samples of 
blood and urine retrieved from 118 women with preterm severe preeclampsia (sPE, n=79) 
and indicated preterm birth as compared to women with uncomplicated pregnancies who 
delivered at term (CRL, n=39). There was no statistical difference in gestational age at 
sample collection between the two groups (mean ± SEM gestational age sPE: 29.7 ± 
0.6wks vs. CRL: 30.7 ± 0.6 wks, t-test P=0.171). As demonstrated in Figure 11, we 
found CML and CML auto-antibodies were present in the blood and urine of both severe 
preeclamptic women and normal controls, but no differences were seen between groups.  
As illustrated in Figure 12, however, calculation of fractional excretion indicators 
demonstrated that women with severe preeclampsia appear to have lower fractional 
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excretions of CML when normalized for proteinuria (sPE vs. CRL, P=0.003), suggesting 
that proteinuria of preeclampsia contains a decreased concentration of AGE-modified 
proteins relative to normal pregnancy. Alternatively, the kidneys of preeclamptic women 
may preferentially retain AGE-modified proteins that may participate in kidney tissue 
injury or aging later in life. 
Circulating sRAGE and TNFα are considered markers of the extent of maternal 
RAGE activation and/or systemic inflammation, respectively. We found that women with 
severe preeclampsia had increased circulating levels of sRAGE, thus confirming the state 
of RAGE system activation (Figure 13, P<0.001).  
In a linear regression analysis that included all 118 women in this study, sRAGE 
 
Figure 11: Maternal serum (A & C) and urine (B & D) levels of Nε-carboxymethyl-lysine 
(CML) and CML auto-antibody as measured by sensitive and specific immunoassays. Statistical 
analysis was performed using Mann-Whitney tests. 
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levels were significantly but weakly correlated with TNFα (Spearman R=0.261; 
P=0.004). This relationship did not maintain when the analysis was restricted to 
preeclamptic women alone (n=79, R=0.116; P=0.307).  
Next we were interested in identifying if any factors or combination of factors 
might influence levels of CML. For this purpose we performed a multivariate linear 
regression with CML and CML auto-antibody concentrations or fractional excretions as 
dependent variables and maternal age, parity, gestational age, race and serum levels of 
sRAGE and TNFα as independent variables. The only relationship revealed was that 
women of non-Caucasian race appeared to have higher CML serum levels (P=0.008). 
 
Figure 12: Maternal fractional excretion indicators Nε-carboxymethyl-lysine (CML) and CML 
autoantibody in absolute value (A & C) and corrected for fractional excretion of total proteins (B 
& D). Statistical analysis was performed using Mann-Whitney tests. 
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There was no significant correlation between CML levels in either blood or urine and 
extent of RAGE activation or inflammation. Similarly, the levels of CML auto-antibodies 
did not appear to be determined by any of the above-listed maternal demographical 
variables or by systemic levels of sRAGE or TNFα. 
Lastly, we employed immuno-localization for CML in placental tissue sections 
from women with severe preeclampsia (n=6). We used as control placental tissues from 
gestational age matched women with idiopathic preterm birth and no histological 
chorioamnionitis (n= 6). While we identified clumpy deposits of CML immunoreactive 
proteins in decidua, villous stroma and maternal vascular spaces, there were no 
discernable differences between the groups (Figure 14).  
In summary, although we confirmed that maternal systemic inflammation and an 
elevation in sRAGE activation are phenomena characteristic of preeclampsia, it does not 
appear that an increase in circulating or deposited AGEs is a determinant mechanism.    
 
Figure 13: (A) Serum TNFα, a reflection of the maternal level of systemic inflammation and (B) 
levels of sRAGE, a reflection of maternal RAGE activation in women with severe preeclampsia 





Women with preeclampsia have higher HMGB1 urine levels and higher HMGB1 
fractional excretion. 
We further sought to identify whether HMGB1 is a possible stimulus driving 
RAGE activation and the increased maternal serum sRAGE levels in preeclampsia. This 
case control study included three groups of time-matched blood and urine samples from 
136 women with either preterm severe preeclampsia and indicated preterm birth (sPE, 
n=79), uncomplicated pregnancies delivered at term (CRL, n=44) or chronic 
hypertension but no preeclampsia (crHTN, n=13). There was no statistical difference in 
gestational age at sample collection between the three groups (mean ± SEM gestational 
age sPE: 30.6 ± 0.4 wks vs. CRL: 30.1 ± 0.7 vs. crHTN: 31.1 ± 1.4 wks, one-way 
ANOVA P=0.295). We measured serum levels of sRAGE as a marker of RAGE 
activation and TNFα as a marker of TLR activation (Figure 15). We found that only 
 
Figure 14: CML immunohistochemistry in paraffin-embedded sections of a representative 
preeclamptic placenta (sPE, a) and a gestational age matched control (CRL, b) from a woman 
with idiopathic preterm birth. Negative control slide with omitted first antibody (c). Chromogen: 
Ni-DAB, no counterstain. Magnification: Bar =50µm. 
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sRAGE upregulation is a phenomenon specific for preeclampsia while the increase in 
TNFα is not specific to preeclampsia and rather similarly elevated in chronic 
hypertension.  
We next analyzed serum and urine levels of HMGB1 and found that urine but not 
serum HMGB1 levels were significantly elevated in severe preeclampsia (P<0.001), 
independent of gestational age. The chronic hypertension group was not statistically 
different from either severe preeclampsia or controls (Figure 16). Furthermore, we found 
that urinary excretion of HMGB1 correlated with circulating sRAGE (r=0.426, P<0.001), 
proving that the increased excretion of HMGB1 in preeclampsia directly correlates with 
the extent of RAGE activation. 
We next calculated the fractional excretion of total protein and the fractional 
excretion of HMGB1. The fractional excretion of HMGB1 was significantly increased in 
 
Figure 15: (A) Serum TNFα, a reflection of the maternal level of systemic inflammation and (B) 
levels of soluble RAGE (sRAGE), a reflection of maternal RAGE activation in women with 
severe preeclampsia (sPE, n=79), normal women (CRL, n=44) and women with chronic  
hypertension (crHTN, n=13). Statistical analysis was performed using one-way ANOVA and 
Student-Newman Keuls post-hoc tests. 
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severe preeclampsia as compared to controls and women with chronic hypertension 
(Figure 17A, P<0.01).  
We then asked whether presence or absence of end-organ disease, defined as 
eclampsia (n=5), HELLP (n=20) or intrauterine growth restriction (IUGR n=18), 
 
Figure 16: (A) Serum HMGB1 and (B) urine HMGB1 concentrations in women with severe 
preeclampsia (sPE, n=79), normal women (CRL, n=44) and women with chronic  hypertension 
(crHTN, n=13). Statistical analysis was performed using one-way ANOVA and Student-
Newman-Keuls post-hoc tests. 
 
 
Figure 17: (A) Fractional excretion of HMGB1 in women with severe  preeclampsia (sPE, 
n=79), normal women (CRL, n=44) and women with chronic  hypertension (crHTN, n=13). (B) 
Analysis with the severe preeclampsia group divided into women with end-organ disease as 
defined by eclampsia and/or HELLP (sPE+: n=23) or without end-organ disease (sPE−: n=26). 
Statistical analysis was performed using one-way ANOVA. * denotes P<0.05 vs. all other groups. 
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impacted the levels of HMGB1 in severe preeclampsia. Analysis of the data using these 
categories showed that women with eclampsia and/or HELLP had elevated urine 
HMGB1 concentrations (P=0.026) and fractional excretions (P<0.001) compared to those 
with severe preeclampsia but no end-organ disease or IUGR. This difference maintained 







This study is the first to compare and contrast two modes and putative stimuli of RAGE 
activation as related to two important causes of prematurity: intra-amniotic inflammation, 
an important pathogenic pathway for spontaneous preterm birth and antenatal fetal injury, 
and preeclampsia, the most important cause of mandated preterm delivery. 
8. 1. Spontaneous preterm birth: infection and inflammation 
Our research supports a role for fetal HMGB1-RAGE system activation in intra-amniotic 
infection and inflammation. We found that women with severe intra-amniotic 
inflammation had significantly increased amniotic fluid HMGB1 compared to women 
with absent and mild inflammation. We further showed that cord blood HMGB1 
significantly correlated with the levels of cord blood IL-6 and S100B protein. In fact, 
cord blood HMGB1 level was the sole predictor of elevated S100B protein, independent 
of gestational age at delivery, histological chorioamnionitis, PPROM, race or cord blood 
IL-6 level, and, importantly, S100B did not vary significantly with any other maternal or 
fetal variable tested, except for the cord level of HMGB1. In addition, we found that cord 
blood sRAGE also increases with gestational age. Notably, cord blood HMGB1 levels are 
significantly higher compared to both sRAGE and S100B, identifying HMGB1 as an 
important signaling molecule for the fetus. 
The high level of association between S100B and HMGB1 independent of 
gestational age is compelling evidence for a role of alarmins as mediators of perinatal 
complications. It is important to note that both HMGB1 and S100B are ligands of RAGE, 
and both are antagonized by the decoy receptor sRAGE [133]. Previous studies 
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investigating the presence of the RAGE axis in pregnancy demonstrated that sRAGE is 
present in amniotic fluid and increases with gestational age, which may account for the 
higher incidence of inflammation-related preterm deliveries at earlier gestational ages 
[132].  
Despite many studies linking blood and CSF levels of S100B with brain injury, 
several authors have argued against the potential of cord blood S100B to serve as 
predictor of brain damage in newborns. This reluctance was based on the assumption that 
S100B immunoreactivity was also detected in the placenta [193]. It was therefore 
postulated that placental damage may also contribute to the S100B measured in cord 
blood. While there is no published study to date that validates this assumption, our data 
argue to the contrary. Since cord blood S100B has no relationship with the presence, 
absence or severity of histological chorioamnionitis, it is unlikely that S100B transfers to 
cord blood from a damaged placenta. Moreover, cord blood S100B levels in normal 
pregnancy measure higher than those in amniotic fluid and maternal blood [194]. The 
concentration gradient therefore favors transfer from the fetus to the amniotic fluid or 
maternal compartment and not vice versa [57]. This contrasts with IL-6, where the 
concentration gradient favors transfer to the fetus and is highly dependent on a damaged 
placenta, as we showed in an analysis of the same cohort of preterm neonates [57]. Due 
to the biological implications of an elevated S100B level for the fetus, we further argue 
that the source may be unimportant. Regardless of the origin, S100B remains a potent 
activator of RAGE and mediator of cytotoxicity.  
 Intrauterine infection is an important cause of preterm birth and is thought to be 
a chronic process leading to adverse outcomes that eclipse the effects of prematurity 
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alone. Intrauterine infection and subsequent inflammation contributes disproportionately 
to neonatal mortality and morbidity. The results of the ORACLE I and II clinical trials 
showed an increased risk of cerebral palsy when antibiotics were given to women in 
threatened preterm labor or with PPROM, suggesting that antibiotics fail to suppress the 
processes leading to fetal cellular damage despite inducing suppression of bacteria. 
Prolonging fetal exposure to such a damaging environment by delaying labor in this 
context, therefore, may cause further harm to the fetus. Thus, identifying markers of 
inflammation that may appear prior to the onset of clinical signs and symptoms of 
intrauterine infection is crucial to improving outcomes. 
8. 2. Medically indicated preterm birth: preeclampsia 
Our research further supports a role for a different type of HMGB1-RAGE axis activation 
in preeclampsia that is characterized by elevated maternal compartment sRAGE. We 
identified HMGB1 as a potential stimulus driving this RAGE activation given that 1) 
urine but not serum HMGB1 levels were significantly elevated in severe preeclampsia, 
independent of gestational age, 2) the fractional excretion of HMGB1 was significantly 
increased in severe preeclampsia as compared to controls and women with preexisting 
hypertension but no preeclampsia, and 3) HMGB1 urinary excretion correlated with 
circulating soluble RAGE. Importantly, we also found that the increased fractional 
excretion of HMGB1 relates to disease severity and end-organ involvement. Severe 
preeclamptics with end-organ involvement, as defined by HELLP or eclampsia, have 
higher fractional excretions of HMGB1 than those without such manifestations. These 
results suggest that the DAMP HMGB1 may play a role in fueling RAGE activation in 
women with severe preeclampsia.  
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HMGB1 is known to be a hydrophobic, “sticky” protein, and thus its elevated 
excretion but lack of detectable change in serum may be the result of its adherence to 
vascular endothelium or preferential elimination by the preeclamptic kidney. 
Alternatively, it is possible that HMGB1 has increased nephritic production that leads to 
increased excretion without detectable serum changes.  
In contrast to HMGB1, however, our data does not support a role for excess 
AGEs in RAGE system activation, as evidenced by the lack of increase in CML or CML 
auto-antibody levels in severe preeclamptics as well as the lack of correlation between 
CML or CML auto-antibody levels with soluble RAGE. 
Preeclampsia is the leading cause of a medically indicated preterm birth and a 
major cause of maternal and fetal morbidity and mortality. Preeclampsia, which accounts 
for 15 percent of preterm births [78,79] and is responsible for 20 percent of pregnancy-
related maternal deaths in the United States [80], is a disease with high medical and 
economic impact. And yet preeclampsia remains a poorly understood disorder. While 
clinical signs and symptoms often make the diagnosis relatively simple, no diagnostic 
tools exist to definitively diagnose preeclampsia. Given the substantial risks to the mother 
and fetus, it is crucial that research uncover an improved understanding of the etiology of 
preeclampsia, which may lead to effective prevention and/or treatment of this serious 
disease.  
Previous research has shown that severe preeclampsia is characterized by RAGE 
system activation, which leads to inflammation, oxidative stress and endothelial injury. 
This RAGE pathway activation may be involved in fueling some of the pathophysiologic 
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